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Abstract 
 
Study Purpose: The purpose of this study was to examine whether there were differences in 
patterns of care between African American (AA) and Non-Hispanic White (NHW) men newly 
diagnosed with prostate cancer in Florida, and how the treatment patterns compare with the 
National Comprehensive Cancer Network (NCCN) initial treatment recommendations.  
Materials and Methods: This retrospective cohort study utilized data from the Florida Cancer 
Data System (FCDS), to identify incident cases of prostate cancer diagnosed between 1982 and 
2012. The variables of interest included: race/ethnicity, marital status, age at diagnosis, stage at 
diagnosis, tumor grade, year of diagnosis, and treatment modality (singular or multimodality).  
Adjusted odds ratios (AORs) and 95% confidence intervals were calculated to determine 
disparities in the receipt of treatment by age at diagnosis, stage at diagnosis and tumor grade 
between AA and NHW men.   
Results:  A total of 244,449 AA (30,556 cases or 12.5%) and NHW (213,893 cases or 87.5%) 
men met the study inclusion/exclusion criteria.  AA men were significantly less likely to receive 
surgery only or surgery in combination with other treatment modalities compared to NHW men, 
localized disease (AOR=0.66, 95% CI (0.63-0.68), regional disease (AOR=0.63, 95% CI (0.57-
0.71), distant disease (AOR=0.50, 95% CI (0.34-0.75).  Comparisons of adherence to the 
NCCN initial treatment recommendations indicate that AA men with <10 years of life expectancy 
had a lower NCCN initial treatment adherence percentage compared to NHW men (5% versus 
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13%).  Moreover, AA men in the very high risk group had a higher NCCN initial treatment 
adherence percentage compared to NHW men (76% versus 70%). 
Conclusion:  After adjusting for potential demographic and clinical confounders, significant 
differences exist in the receipt of first course of treatment where AA men were more likely to 
receive radiation and/or hormone therapy and less likely to receive surgery compared to NHW 
men.  Further research is needed to address this disparity. 
viii 
 
  
 
CHAPTER ONE: INTRODUCTION 
Geographic Variation in Prostate Cancer (PrCa) 
Internationally, PrCa is the one of the most commonly diagnosed cancers among men, 
second only to lung cancer (IARC, 2008).  In 2008, Australia and New Zealand had the highest 
age-adjusted incidence rate of PrCa at 104.2 per 100,000 men while South and Central Asia 
had the lowest age-adjusted incidence rate at 4.1 per 100,000 men (IARC, 2008).  To show 
variability of prostate cancer incidence within the same continent, men in Southern Africa had 
an age-adjusted incidence rate of PrCa of 61.8 per 100,000 men while Northern African men 
had an age-adjusted incidence rate of 10.5 per 100,000 men (IARC, 2008).  In the United States 
(U.S.), the American Cancer Society (ACS) estimated ~1.7 million newly diagnosed reportable 
cancer cases in 2013, with 28% of the newly diagnosed cases expected to be men with PrCa 
(ACS, 2013).   
Race/Ethnic Differences in PrCa Incidence and Mortality 
Stratifying the PrCa incidence rates by race and ethnicity, African American (AA) men in 
the U.S. have the highest incidence of PrCa at 236 per 100,000 men while Hispanic men have 
the lowest PrCa incidence at 126 per 100,000 men, Table 1 (SEER, 2011).    
The age-adjusted incidence rate of PrCa in Florida from 2005-2009 was 137.7 per 
100,000 men (ACS, 2013). The state with the highest age-adjusted incidence rate of PrCa was 
the District of Columbia (D.C.) with 185.1 per 100,000 men while Arizona had the lowest age-
adjusted incidence rate of PrCa with 118.1 per 100,000 men (ACS, 2013).  In Florida, from 1981 
to 2008 the incidence gap of PrCa between AA men compared to White men has steadily 
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increased (Ren et al, 2012).  Comparing the incidence rate of PrCa in Florida to the incidence 
rate of PrCa globally, Florida has a high age-adjusted incidence rate of PrCa; therefore, this 
study will focus on the burden of PrCa disease in Florida.    
Table 1.  Summary of Surveillance Epidemiology and End Results (SEER) Cancer and PrCa 
Incidence Rates per 100,000 men by Race and Ethnicity in the U.S., 2005-2009.  
Race/Ethnicity Cancer Incidence 
Rate* 
PrCa Incidence Rate 
All Races 541.0  154.8  
Asian/Pacific Islander 342.6  146.9  
Black 626.1  236.0  
Hispanic 360.2  125.9  
White 543.6  146.9  
Source: SEER, 2011 
*All cancers included 
In terms of mortality, men in the Caribbean Islands have the highest PrCa mortality rate 
at 26.3 per 100,000 men while Asian men have the lowest PrCa mortality rate at 2.5 per 
100,000 men (IARC, 2008). In the U.S., over 580,000 cancer deaths were expected in 2013 
with 10% of the cancer deaths attributed to PrCa (ACS, 2013).  In addition, U.S. AA men have 
the highest PrCa mortality rate at 53 per 100,000 men while Asian/Pacific Islander men have 
the lowest PrCa mortality rate at 10 per 100,000 men, Table 2 (SEER, 2011).   
Evaluating the PrCa mortality rates by U.S. state and/or territory, men in D.C. had the 
highest age-adjusted mortality rate of 41.3 per 100,000 men while men in Hawaii had the lowest 
age-adjusted mortality rate of 16.2 per 100,000 men (ACS, 2013).  The age-adjusted mortality 
rate of PrCa in Florida from 2005-2009 was 19.6 per 100,000 men (ACS, 2013).  Lastly, AA 
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men diagnosed with PrCa in Florida have a higher mortality rate compared to White men (Ren 
et al, 2012).   
Table 2.  Summary of SEER Cancer and PrCa Mortality Rates by Race and Ethnicity per 
100,000 men in the U.S., 2005-2009. 
Race/Ethnicity Cancer Mortality Rate* PrCa Mortality Rate 
All Races 222.4  23.6  
Asian/Pacific Islander 132.6  10.0  
Black 296.5  53.1  
Hispanic 150.5  17.8  
White 222.5  21.7  
Source: SEER, 2011 
*All cancers included 
 
Disparities in Survival and Stage at Diagnosis for Patients with PrCa 
In addition to the race and ethnic differences in incidence and mortality among men 
diagnosed with PrCa, the same disparity trend is observed in the relative PrCa survival time and 
stage of disease at diagnosis.  The relative PrCa survival among AA men is lower at 1 year, 5 
years and 10 years compared to other race and ethnic groups (SEER, 2012). Brawley and 
colleagues suggest that AA men have a poorer PrCa survival rate compared to White men 
because of a lack of access to quality health care and a lack of access to cancer related 
treatment (Brawley, 1999).  Five years later, Ward and colleagues emphasized these socio-
economic barriers when they evaluated cancer disparities by race/ethnicity and socioeconomic 
status (SES) (Ward, 2004).  For example, they identified low income, not graduating from high 
school, inconsistent source of health insurance and not having recommended cancer screening 
tests as reasons for the disparities in contributing to the increase in the cancer mortality rate 
among minorities (Ward, 2004).  
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Approximately 80% of all PrCa tumors are diagnosed at localized stage (SEER, 2012); 
indicating that the disease is confined within the prostate gland and has not metastasized.  
However, AA men are more likely to be diagnosed with advanced disease (SEER, 2012), which 
indicates that the disease has spread beyond the prostate gland.  From a clinical perspective 
this is pertinent because stage at diagnosis is an important predictor of survival, and informs 
treatment recommendations (Hoffman RM et al, 2001).  The current literature shows an 
increase in the number of AA men that do not seek or obtain preventive health care in order to 
detect PrCa at an early stage (Ward et al, 2004; Hoffman et al, 2001; Roetzheim et al, 1999; 
Shavers et al, 2002).  PrCa has a disproportionately high burden among AA men in the U.S. 
and Florida because they are more likely to have a higher incidence rate, higher mortality rate, 
more likely to be diagnosed with advanced disease at diagnosis, more likely to be diagnosed at 
a younger age and less likely to live longer compared to White, Asian and Hispanic men (SEER 
FastStats, 2012).   
Disparities in Treatment for Patients with PrCa 
The treatment modalities administered to PrCa patients have been shown to vary, with 
advanced stage patients being under-treated and early stage patients being over treated 
(Cooperberg, 2010; CECS, 1999; Shahinian et al, 2006; Wilt et al, 2008; Moyer, 2012; Shimer, 
2013).  In addition, the decision making process regarding treatment is influenced by the patient 
and physician treatment preferences.  For example, the physicians’ knowledge of multiple 
treatments, willingness to suggest more than one treatment and/or proficiency to perform more 
than one treatment have been shown to influence physician treatment preferences (O’Connor, 
2004; Wennberg, 2011; McCoy et al, 1995).   Among 900 men in Florida 65 years of age and 
older it was determined that AA men were less likely to have a digital rectal examination (DRE) 
compared to White men and the contributing factors for not having the DRE was a 
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misconception, by the patient, that it was not necessary or there were no medical issues to 
justify a need for the DRE (McCoy et al, 1995).  Mettlin and colleagues analyzed treatment data 
from the National Cancer Data Base (NCDB) among newly diagnosed PrCa patients in the U.S. 
and determined that AA men were more likely to elect no treatment and less likely to consent to 
radical prostatectomy as part of first course of treatment compared to White men (Mettlin et al, 
1997).  There were no differences in the percentage of AA and White men that elected to have 
radiation therapy; however, the authors concluded that more work is needed because there is 
variation in PrCa treatment modalities by race, age and geographic region (Mettlin et al, 1997).  
Powell and colleagues determined that race/ethnicity is dependent on age at diagnosis, stage of 
disease and year of diagnosis and this guides the treatment outcome for patients with prostate 
cancer (Powell et al, 2004)   
Summary of PrCa Disparities 
There are many reasons why health-seeking behaviors among AA men may not be 
similar to Non-Hispanic White (NHW) men or men in other race/ethnic groups.  For example, 
there are various social determinants, psychosocial factors and health-seeking related 
behaviors that play a role in men being diagnosed at an early stage versus an advanced stage 
(Ward et al, 2004; Hoffman et al, 2001; Roetzheim et al, 1999; Shavers et al, 2002; Lintz et al, 
2003).  For example, men diagnosed with advanced stage PrCa are more likely to be depressed 
prior to their diagnosis (Lintz et al, 2003).  In addition, access to a specialist such as a 
genitourinary oncologist, proximity of primary residence to the closest health facility, fear of the 
unknown, fear of healthcare professionals, fear of dying, fear of invasive or surgical procedures, 
fear of having a DRE, lack of healthcare professionals that look like the patient, history of 
discrimination (i.e. Tuskegee Syphilis Study) and the lack of available transportation all play a 
role in AA men being diagnosed at an early stage versus advanced stage (Ward, 2004; 
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Shavers, 2002, Shavers, 2004).  Moreover, Jones and colleagues indicate that racial 
differences in stage at diagnosis for PrCa cases is significantly correlated with education, 
occupational rank and not fully understanding insurance coverage (Jones et al, 2008).  In 
addition, Potischman and colleagues hypothesize that hormonal exposures in utero to 
testosterone and progesterone may contribute to disparities in cancer risk (Potischman et al, 
2005).  For example, the authors collected serum at the first prenatal visit and determined that 
AA women had higher hormone concentrations of androstenedione, testosterone, estradiol and 
progesterone compared to Hispanic and Caucasian women (Potischman et al, 2005). Stratifying 
the results by years of education, AA women still had higher concentrations of the same 
aforementioned hormones compared to Hispanic and Caucasian women (Potischman et al, 
2005).  This study suggests that further research is needed regarding the mother’s exposures, 
in utero hormonal exposures, and the impact of the mother’s exposure over time to the child.  
All of the aforementioned factors have not been shown to solely explain why AA men 
with certain demographic and clinical characteristics have an increased risk of developing PrCa 
versus NHW men nor have the factors been shown to solely determine why AA men are more 
likely to be diagnosed at an advanced stage.   
There is a gap in the current literature regarding the first course of 
treatment/management strategies received by AA men in Florida newly diagnosed with PrCa, by 
age at diagnosis and stage at diagnosis/tumor grade, and how the first course of 
treatment/management strategies compare to NHW men. Furthermore, it is unknown how the 
treatment modalities administered compare to the treatment recommendations of the National 
Comprehensive Cancer Network (NCCN).  This study explored the differences in 
treatment/management strategies among AA and NHW men in Florida newly diagnosed with 
PrCa. 
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Public Health (PH) Importance of PrCa 
Florida has the third highest number of new cancer cases in the U.S., behind California 
and Texas (ACS, 2013).  AA men have been identified as a high risk group for developing PrCa 
(AUA, 2013; ACS, 2000) and various studies have evaluated race/ethnic differences in 
treatment patterns among PrCa patients using state and national databases (Shavers et al, 
2004; Mettlin, 1997; Polednak and Flannery, 1992; Shimer, 2013); however, published studies 
that have evaluated race/ethnic differences in treatment patterns of PrCa patients in the State of 
Florida are lacking.  This study will inform healthcare professionals in Florida who work with and 
provide care to PrCa patients about the treatments that their patients receive or do not receive 
based on the NCCN treatment recommendations.  In addition, this study will inform PrCa 
patients about the treatment modalities that are administered and how the patterns of care 
compare to the NCCN treatment recommendations.  The results of this study are generalizable 
to men newly diagnosed with PrCa who received all or part of their first course of treatment in 
the State of Florida and their data is reported to the Florida Cancer Data System.  The results of 
the study can be used to educate clinicians, healthcare professionals, and patients on the 
race/ethnic treatment disparities in Florida among patients newly diagnosed with PrCa.  
Research Hypotheses and Specific Aims 
Hypothesis 1 
There are differences in the first course of treatment patterns between AA men and NHW men 
newly diagnosed with PrCa in Florida by stage at diagnosis/tumor grade and age at diagnosis. 
Aim 1 
To compare the first course of treatment modalities received by newly diagnosed PrCa 
patients in Florida between AA and NHW men with the same stage at diagnosis/tumor 
grade and age at diagnosis. 
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Hypothesis 2 
The treatment modalities administered to AA men and NHW men newly diagnosed with PrCa in 
Florida may differ from recommended treatment as per NCCN guidelines among men with the 
same stage at diagnosis/tumor grade, age at diagnosis and life expectancy. 
Aim 2 
To determine if the treatment modalities administered to AA men and NHW men differ 
from the treatment recommendations of the NCCN among men with the same stage at 
diagnosis/tumor grade, age at diagnosis and life expectancy. 
Study Purpose 
This study was designed to enhance the current body of knowledge as it relates to 
detectable differences in treatment strategies among AA and NHW men in Florida newly 
diagnosed with pathologically confirmed PrCa and to assess how these strategies embody the 
contemporary NCCN treatment recommendations. 
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CHAPTER TWO: LITERATURE REVIEW  
Study Background and Rationale 
Anatomy of the Prostate Gland 
Signaled by androgens, specifically testosterone, which is produced in the scrotum, the 
prostate gland is part of the male reproductive system and starts developing before birth and 
continues to grow throughout puberty, with growth of the prostate gland slowing down at 
adulthood (ACS, PC Overview, 2013).  Anatomically located inferior to the bladder and anterior 
to the rectum, the purpose of the prostate gland is multi-faceted.  First, the prostate gland aids 
in creating fluid that protect and nourish the sperm (ACS, PC Overview, 2013).  Secondly, the 
prostate gland, working with the nervous system, serves as a valve to release sperm or urine 
(ACS, PC Overview, 2013).    
 The type of tissue that comprises the prostate gland is primarily epithelial tissue.  
Bostwick and colleagues indicate that approximately 95% of the PrCa tumors arise from the 
epithelial cells producing histology of adenocarcinoma (Bostwick et al, 1989).  Adenocarcinoma 
of the prostate gland was the focus of this study; the rare PrCa histologic types that comprise 
5% of PrCa cases, such as mucinous, ductal, neuroendocrine and small cell carcinoma were 
not addressed (Bostwick et al, 1989). 
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 Figure 1.  Anatomy of the Prostate 
Picture retrieved from the American Cancer Society on August 15, 2013 
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-what-is-prostate-
cancer) “Reprinted by the permission of the American Cancer Society, Inc.  All rights reserved” 
as set forth on Exhibit A. 
Prostate specific antigen (PSA) test 
The PSA test is a blood test that quantifies the amount of the protein, called PSA, in the 
prostate gland (Garnick, 2012).  In 1986, the Federal Drug Administration (FDA) approved the 
use of the PSA test for continuous monitoring of PrCa disease progression and in 1994 the PSA 
test was approved to be used along with the digital rectal examination (DRE) to test for PrCa in 
men with no clinical symptoms (Littrup et al, 1992; NCI, 2012).  An elevated PSA level is 
considered to be above 4.0 ng/mL; however, Henderson and colleagues suggest differences in 
race specific reference PSA values where AA men have a statistically significant higher normal 
PSA level compared to White men (Henderson et al, 1997).  In a study conducted among 
military men, Moul and team concluded that AA men newly diagnosed with PrCa had 
statistically significant higher PSA values at the time of diagnosis compared to White men, 
p<0.001 (Moul et al, 1995).  In addition, Thompson and colleagues suggest there is no 
consensus on the PSA normal upper limit (Thompson et al, 2004).  On the other hand, 300 
Turkish men were administered a transrectal ultrasound (TRUS) biopsy of the prostate if they 
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had an abnormal DRE or a serum PSA over 2.5 ng/ml (Eskicorapci et al, 2004).  Internationally, 
this suggests no consensus on the PSA normal range and if the PSA normal upper limit should 
be standardized by race/ethnicity.  Therefore, based on the results of the receiver operating 
characteristic (ROC) curve, Thompson et al recommend multiple PSA measurements over a 
period of time versus a single PSA measurement in order to determine if a PSA value is 
elevated or not (Thompson et al, 2005).  This methodology allows clinicians to determine the 
normal upper limit for each individual patient, regardless of race/ethnicity. 
In addition to there being no consensus on the PSA normal upper limit, there is also 
controversy on whether the PSA test is used to potentially over diagnose or over treat low risk 
prostate tumors due to the potential risks to the patient outweighing the benefits (Moyer, 2012; 
Carroll P et al, 2009; Wolf, 2010; Lim et al, 2008; Barry, 2009).   For example, an elevated PSA 
level does not equate to a man having PrCa (Moyer, 2012).  Men with confirmed prostatitis, 
urinary tract infection (UTI), benign prostatic hyperplasia (BPH), and men with prior history of a 
biopsy or prostatectomy have been shown to have an elevated PSA level (Dalton, 1989; Neal et 
al, 1992; Collins et al, 1993; Nadler et al, 1995; Ulleryd et al, 1999).  Also, Barry suggests that 
only a quarter of men had PrCa out of those who had a prostate biopsy after confirmation of an 
elevated PSA value (Barry, 2001). Does this mean that 75% of the men in the study with an 
elevated PSA value were potentially over treated? The verdict has yet to be determined.   
The United States Preventative Services Task Force (US PSTF) recommend that all 
men regardless of age should not have PSA screening because it will lead clinicians to over 
treat patients for PrCa that may not cause any major symptoms that warrant any type of 
invasive treatment (Moyer, 2012).  The US PSTF recommendation is that an elevated PSA 
value does not indicate that a man will develop a tumor that is clinically significant (Moyer, 
2012).  One of the major limitations with the US PSTF recommendation is that there is no 
differentiation in the recommendation for low risk versus high risk men, all men are categorized 
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together, regardless of risk (Moyer, 2012).  On the other hand, the American Urological 
Association (AUA) updated their PrCa screening recommendation in April 2013 and added a 
recommendation for PSA screening by age (AUA, 2013).  For example, the AUA does not 
recommend PSA screening among men 40 years of age and younger as well as no annual PSA 
screening among men 40 to 54 years of age (AUA, 2013).  In addition, the AUAs prostate 
screening recommendation for high risk men is that it should be addressed on a case by case 
basis (AUA, 2013).  The ACS has a different recommendation from the US PSTF and AUA 
regarding PrCa screening and they provide additional detail on recommendations for high risk 
groups (ACS, 2013).  For example, the ACS state that it is pertinent for every male to have a 
discussion with a healthcare professional before making any treatment decisions (ACS, 2013).  
In order to determine the best course of action for screening, AA men should start this 
discussion at age 45 since they are more likely to be diagnosed with PrCa before the age of 50, 
while men with more than one first degree relative diagnosed with PrCa should start this 
discussion at age 40 (ACS, 2013).  Based on the aforementioned recommendations from the 
US PSTF, AUA and ACS there is no documented consensus for PSA screening among high 
risk or AA men at the national level.   
Andriole and colleagues with the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial determined that the rate of death from PrCa was similar among the case group 
and the control group when evaluating men who had an annual PSA screening (Andriole et al, 
2012). One limitation for this study is that there was no stratification by race/ethnicity in order to 
determine if the rate of death from PrCa was similar between race/ethnic groups.  On the other 
hand, the European Randomized Study of Screening for Prostate Cancer (ERSPC) concluded 
that men who had a PSA screening had a decreased rate of death from PrCa compared to 
those who had no PSA screening (Schroder et al, 2012).  The conclusion of these population 
based studies having opposite or different results adds to the current controversy on whether 
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the PSA test should be utilized as a screening tool.  Garnick state that the PSA test should be 
primarily used, from a clinical perspective, after a man has been diagnosed with PrCa versus 
using it as a screening tool to identify PrCa (Garnick, 2012). 
Another concern with utilizing the PSA test as a screening tool is that it lacks the ability 
to differentiate between aggressive prostate tumors versus slow growing prostate tumors 
(Garnick, 2012; Moyer, 2012; Hill, 2013).  From a clinical perspective, this lack of detail with the 
PSA test further convolutes the controversy on the use and benefit of the PSA screening test.  
Hill and colleagues conducted a case control study among military men to determine if there 
were any clinical laboratory biomarkers that could be used in conjunction with the PSA test to 
obtain a clinical rule for administering a prostate biopsy (Hill, 2013).  The authors determined 
that hemoglobin count, red blood cell count, serum creatinine count, the mean corpuscular 
volume and AA race were significantly associated with PrCa stages 2 through 4 compared to 
stage 1 (Hill, 2013).  From a clinical perspective, this study contributed to the current body of 
knowledge because the additional clinical laboratory biomarkers may be used to clinically 
determine aggressive versus non-aggressive tumors which may allow clinicians to make 
appropriate treatment decisions and/or recommendations. 
In summary, Garnick suggest that PSA screening followed by delayed treatment may be 
a feasible compromise to the current controversy on the effectiveness of the PSA screening test 
(Garnick, 2012); however, the verdict has yet to be determined because this forethought in 
delaying treatment may not be wise for all men diagnosed with PrCa, especially for high risk or 
AA men. 
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Diagnosis of PrCa 
Although there is controversy around the use of the PSA test as a screening tool, the 
PSA test, the DRE and a biopsy of the prostate are the current methods being used to diagnose 
PrCa (Schroder et al, 1998; Littrup et al, 1994).  Combined reviews of both the PSA test and the 
DRE results provide a clinician with guidance to make prognostic and treatment 
recommendations if one or both test results are abnormal or positive (Moyer, 2012; Garnick, 
2012).  In addition, other factors such as age and life expectancy are also considered 
(Stangelberger et al, 2008; Albert and Clark, 2008; Moul and Mouraviev, 2008).  For example, 
considering the other demographic and/or clinical factors, if one or both test results are positive 
or abnormal then a clinician may recommend a TRUS guided needle biopsy of the prostate to 
confirm the presence of cancer (Garnick 2012; Moul and Mouraviev, 2008).  Eskew and 
colleagues performed a TRUS on patients if the DRE was abnormal or if the PSA result was 
above 4.0 ng/ml among 100 patients within a year to compare the 5 region biopsy methodology 
and the sextant biopsy methodology (Eskew, 1997).  If the biopsy result is positive for cancer 
then the physician may recommend invasive or non-invasive first course of treatment options.  
Treatment Modalities 
After a patient has pathologic confirmation of PrCa it is important to evaluate all potential 
treatment options which are guided by multiple clinical factors such as clinical tumor node and 
metastasis (TNM) stage, age of the patient at diagnosis, and life expectancy (Netto and Cheng, 
2012; Moyer, 2012).  The treatment options that are available for men diagnosed with PrCa 
include watchful waiting, active surveillance, cryosurgery, surgery (prostatectomy), radiation, 
hormone therapy, chemotherapy or immunotherapy (ACS, 2013).  Watchful waiting, active 
surveillance, surgery or radiation are treatment options that are commonly administered to men 
diagnosed with early stage or localized PrCa while men diagnosed with regional, advanced or 
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metastatic PrCa are commonly administered hormone therapy, chemotherapy, or 
immunotherapy (Mettlin et al, 1997; Polednak and Flannery, 1992; Shavers et al, 2004; 
Cooperberg et al, 2010; Albertsen et al, 1998).  Cryosurgery has been used to treat both 
localized and advanced PrCa (Henderson and Davies, 2012).  In reviewing the literature, 
advanced stage PrCa or PrCa disease progression is known by but not limited to the following 
nomenclature: “castrate-resistant”, castration-recurrent”, “hormone resistant” and “androgen-
insensitive” (Hotte and Saad, 2010).  These nomenclature were utilized in the literature search 
in order to understand the treatment options for men diagnosed with advanced PrCa since AA 
men and high risk men are more likely to be diagnosed with advanced stage disease at 
diagnosis (SEER, 2011; ACS, 2013).  
Watchful Waiting versus Active Surveillance 
Watchful waiting or expectant management is defined as not receiving any type of 
invasive or non-invasive treatment after being diagnosed with localized PrCa while active 
surveillance is defined as actively following and monitoring a PrCa patient with annual DREs, 
PSA tests and prostate biopsies (Ip S et al, 2011; ACS, 2013).  One of the fundamental 
differences between watchful waiting and active surveillance is that the intention of active 
surveillance is curative while the intention of watchful waiting is palliative (Ip S et al, 2011).  The 
goal of active surveillance is to monitor the prostate gland to determine if the tumor is slow or 
rapidly growing (Prostate Cancer Foundation, www.pcf.org, 2014).   
The reason for watchful waiting being considered palliative treatment and not curative is 
that treatment usually administered after the first course of treatment plan has been 
implemented is considered to be subsequent or non-first course of treatment (FCDS DAM, 
2013); therefore, treatment administered after the watchful waiting time period is considered 
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disease progression.  Appendix A describes the first course of treatment and how watchful 
waiting is defined, according to FCDS.   
The similarity between watchful waiting and active surveillance is that pathologic 
confirmation of PrCa has been established; however, the decision or intent to treat the PrCa 
was delayed (Garnick, 2012).  In December 2011, the National Institutes of Health (NIH) 
recognized active surveillance as a possible treatment option for men with ‘low-risk PrCa’ 
(Garnick, 2012). 
In a meta-analysis using data from the U.S., Sweden, Israel, and Scotland, Chodak and 
colleagues suggest watchful waiting as a feasible treatment option for men diagnosed with 
grade 1 or grade 2 prostate cancer with a life expectancy of 10 years or less (Chodak et al, 
1994).  However, for men with a life expectancy longer than 10 years, watchful waiting is not 
recommended because the risk of living with metastatic PrCa increases (Chodak et al, 1994).    
Cryosurgery 
Cryosurgery is a surgical procedure where probes (cryoprobes) are used to freeze and 
defrost the entire prostate gland or part of the prostate gland where the foci of tumor is located 
using argon gas (freeze) and helium gas (defrost) (Rees et al, 2004; Harvey, 2006; Henderson 
and Davies, 2011).    Cryosurgery can be used as a single freeze-defrost method or a double 
freeze-defrost method (Henderson and Davies, 2011).  Cryosurgery has been used to treat 
PrCa that is localized, regional, advanced, and as salvage treatment after failed radiation (Rees 
et al, 2004; Harvey, 2006; Henderson and Davies, 2011); however, there is currently no gold 
standard in which cryosurgery should be performed (Rees et al, 2004; Harvey, 2006; 
Henderson and Davies, 2011).   When the procedure was first introduced in the 1960s, it was 
not well accepted because of the ‘high complication rates’ and the PrCa recurrence rate was 
greater than 70% (Rees et al, 2004).  The side effects versus benefits of cryosurgery have also 
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been evaluated.  For example, erectile dysfunction is the primary complication affecting up to 
96% of the men who have cryosurgery (Henderson and Davies, 2011).  In addition, the ACS 
report that 4 out of 5 men have damage to the nerves surrounding the prostate gland after 
surgery (ACS, 2013).    
Surgery 
A prostatectomy is the surgical removal of the prostate gland and there are different 
facets of a prostatectomy such as a subtotal prostatectomy where the prostatic capsule may or 
may not be left intact, a radical or total prostatectomy where the prostate, prostatic capsule, 
ejaculatory ducts and seminal vesicles are removed and a prostatectomy that involve the 
removal of other organs such as the bladder (ACS, 2013; FCDS DAM, 2013).  The details of the 
prostate cancer surgeries are discussed in Chapter 3. 
Currently there is no consensus on the best treatment modalities for early stage or 
localized PrCa patients (Moyer, 2012; Xiao et al, 2013).  Bill-Axelson and colleagues randomly 
assigned early stage PrCa patients to receive surgery or watchful waiting (Bill-Axelson, 2005).  
After 10 years of follow-up, the authors concluded that the patients randomized to receive 
surgery had a lower risk of death compared to the patients randomized to the watchful waiting 
group (Bill-Axelson, 2005).  Utilizing SEER-Medicare linked data, Shavers and team concluded 
that 30% of AA men chose watchful waiting as a treatment option while 23% of White men 
chose watching waiting as a treatment option (Shavers, 2004).  After adjusting for potential 
confounders, the OR associated with the aforementioned conclusion that AA are more likely to 
select watchful waiting as a treatment option was statistically significant (compared AA men to 
White men), OR = 1.4, 95%CI (1.3, 1.6).    AA men are twice as likely to be diagnosed with 
advanced disease (Jones et al, 2008); therefore, this information suggest that AA men may not 
be well informed or educated in selecting the most appropriate treatment option because they 
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are more likely to select watchful waiting which is a palliative treatment option.  Based on the 
long term follow-up results from the study conducted by Bill-Axelson and colleagues, those who 
select watchful waiting have a higher risk of death compared to those who had surgery (Bill-
Axelson, 2005).  In essence, AA men are more likely to select a treatment option where the risk 
of death is higher compared to White men. 
One of the suggested barriers to men selecting a more invasive treatment option such 
as surgery is the potential for impotence.  For example, Murphy and colleagues determined that 
~60% of patients who had a radical prostatectomy were impotent after surgery when they were 
not impotent before surgery (Murphy et al, 1994).  Additionally, in a study of quality of life of 
PrCa patients on Medicare, results from 1,000 men indicate incontinence affected their quality 
of life more than erectile dysfunction (Fowler et al, 1995).  Despite this, ~90% of the men would 
choose to have surgery again (Fowler et al, 1995).  A limitation of this study was that the results 
were not stratified by race/ethnicity in order to determine if there were race/ethnic differences in 
the percentage of men that would choose to have surgery again. 
Radiation Therapy or Radiotherapy 
Radiation therapy or Radiotherapy is defined as the administration of radiation beams to 
the body (ACS, 2013).  There are 2 main types of radiation, external beam radiation and 
brachytherapy (internal radiation therapy) (ACS, 2013).  For example, men with localized PrCa 
usually receive external radiation beams to the prostate or radioactive ‘seeds’ are implanted in 
the prostate to halt the spread of cancer outside of the prostate gland (ACS, 2013).  Radiation 
therapy can be administered in parallel with other treatment modalities such as surgery or 
hormone therapy; where hormone therapy is used to shrink an enlarged prostate gland before 
radiation therapy is administered (ACS, 2013).  Radiation therapy is recommended as adjuvant 
therapy after surgery if a patient has positive surgical margins (Leibovich et al, 2000).  More 
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specifically, administering radiation therapy in combination with surgery after confirmation of 
positive surgical margins has been shown to extend the time to first recurrence (Leibovich et al, 
2000).  Laverdiere conducted a clinical trial where 100 patients with localized PrCa were 
randomized into 1 of 3 groups to have radiation therapy only, hormone therapy before radiation 
therapy (neoadjuvant therapy) or hormone therapy before, during and after radiation therapy 
(Laverdiere et al, 1997).  The group that had hormone therapy administered before, during and 
after radiation therapy had a significant rate of lower positive prostate biopsies 12 months post 
treatment (Laverdiere et al, 1997).     
Hormone Therapy 
 Hormone therapy for PrCa patients is primarily for men with disease progression or 
metastatic PrCa (Stangelberfer et al, 2008).  Hormone therapy is also known as androgen 
deprivation therapy or androgen suppression therapy (ACS, 2013) and can be administered to 
shrink the prostate tumor before radiotherapy (Laverdiere et al, 1997).  The hormone therapy 
drugs target the testicles from producing androgens, called anti-androgen drugs, which are 
usually taken orally (ACS, 2013).  In some instances the testicles are surgically removed in 
order to stop the production of androgens (ACS, 2013).   
 De Bono and team evaluated the survival time in patients that previously received 
docetaxel to randomly receive abiraterone and prednisone or a placebo and prednisone (de 
Bono et al, 2011).  The results of the clinical trial indicate that the patients randomized to the 
abiraterone and prednisone group had a longer survival by 4 months (de Bono et al, 2011).  
From the same team, Ryan and colleagues evaluated abiraterone in patients with metastatic 
PrCa that did not previously receive chemotherapy in a double blinded study that randomized 
~1000 patients into two groups (Ryan et al, 2013).  The first group received abiraterone and 
prednisone while the second group received a placebo and prednisone (Ryan et al, 2013).  The 
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authors determined that the first group, those who received abiraterone and prednisone, had a 
longer progression free survival compared to the second group by 8 months (Ryan et al, 2013).  
 In a double blinded study evaluating the use of enzalutamide after chemotherapy, ~1200 
men were randomized to receive the drug or a placebo (Scher et al, 2012).  The results of the 
clinical trial indicate that the men who received enzalutamide had a longer survival by 5 months 
compared to the placebo group (Scher et al, 2012).  In a randomized clinical trial evaluating 
bone metastasis in men with primary PrCa that may or may not have previously received 
chemotherapy, Parker and colleagues administered radium 223 injections or a placebo injection 
and determined that the patients who received the radium 223 injections had a longer survival of 
3 months compared to those who received the placebo injections (Parker et al, 2013). 
Chemotherapy 
Chemotherapy is defined as the administration of drugs that have been designed to 
attack and halt the growth cycle of cancer cells in the body and they are used to target prostate 
cancer cells that have metastasized to other organs of the body (ACS, 2013).  When men with 
PrCa are administered chemotherapy this usually indicates that hormone therapy was not 
successful (ACS, 2013).   Tannock and colleagues randomly assigned advanced disease PrCa 
patients who previously failed hormone therapy to receive docetaxel and predisone or 
mitozantrone at multiple different dosage levels over varying time periods (Tannock et al, 2004).  
The authors observed that the men randomized to receive docetaxel plus predisone every three 
weeks had a statistically significant reduce rate of death of 24% compared to those in the 
mitozantrone group (Tannock et al, 2004).  On the other hand, Bahal and colleagues evaluated 
the survival time among 2 groups of patients that received mitoxantrone or cabazitaxel among 
metastatic PrCa patients (Bahl et al, 2013).  The authors determined that patients who received 
cabazitaxel lived longer compared to the patients who received mitoxantrone (Bahal, 2013). 
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In summary, based on the aforementioned clinical studies, mitaxantrone has not been 
shown to reduce the rate of death among men with advanced PrCa. 
Immunotherapy 
Immunotherapy for prostate cancer is administered in the form of vaccine therapy (ACS, 
2013).  The goal of the vaccine is to initiate the cells in the body to fight off the prostate cancer 
cells and this treatment modality is administered to men with advanced prostate cancer or men 
who have failed hormone therapy (ACS, 2013; Kantoff, 2010).  Kantoff and colleagues 
conducted a randomized clinical trial and determined that men who were administered 
Sipuleucel-T (Sip-T) immunotherapy had a reduced rate of death by 20% plus they had a longer 
survival of 4 months compared to men who did not receive Sipuleucel-T immunotherapy 
(Kantoff, Higano et al, 2010).  Kantoff and colleagues conducted another randomized phase 2, 
blinded, clinical trial where they evaluated a pox viral vaccine and observed that men 
randomized to the group to receive the poxvirus called “PROSTVAC-PF”, had a 40% reduced 
rate of death and with a median survival time of 10 months compared to the men who did not 
receive the vaccine (Kantoff, Schuetz et al, 2010).  As of 2010, Sip-T is the only Federal Drug 
Administration (FDA) approved immunotherapy drug for prostate cancer (NCI, 2015).  
Summary of PrCa Treatment Modalities 
As previously mentioned, the PrCa treatment modalities can be delivered as a singular 
treatment modality (i.e. radiation only) or the treatment options can be combined over a period 
of time using multiple different treatment modalities (i.e. surgery and radiation).  In addition, men 
can receive multiple different types of the same treatment modality.  For example, men can 
receive external beam radiation and ‘seed’ implants (D’Amico et al, 1998).  Men tend to opt for 
less invasive treatments like watchful waiting or active surveillance versus more invasive 
treatment such as surgery or radiation due to some of the potential risks or potential side effects 
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of having an invasive procedure (Shavers, 2004).  For example, the potential risks associated 
with surgery include but are not limited to incontinence or impotence while the side effects 
associated with radiotherapy include rectal bleeding and/or fecal soiling from the radiation 
beams impacting the bladder and rectum (Garnick, 2012).  In less than 5% of the patients that 
have radiation, a fistula forms between the rectum and bladder where urine leaks from the 
bladder to the rectum (Leibovich et al, 2000).  In addition, the side effects from administering 
hormone therapy, chemotherapy or immunotherapy include increased body weight, decreased 
sex drive, hot flashes, heart irregularities, liver abnormalities and bone thinning (Garnick, 2012).   
PrCa Risk Factors 
There are various modifiable and unmodifiable risk factors associated with PrCa.  For 
example, the American Cancer Society (ACS) indicate that older age, AA men, men with a 
family history of PrCa, genetic variations, obesity, men with diets that include a high proportion 
of red meats or high fat dairy products, men with a positive history of sexually transmitted 
infections such as chlamydia or gonohorrea and men with prostatitis (inflammation of the 
prostate) have an increased risk of developing PrCa (ACS, 2012).  This is a review of the 
literature as it relate to the aforementioned risk factors.  
Age 
The Department of Defense (DOD) determined that there was a 119% increase in the 
number of men diagnosed with PrCa younger than 60 years of age from 1991-2000 (DOD-
CPDR, 1999).  Scardino stated that 30% of men 50 years of age and older have histologic 
confirmation of PrCa at the time of autopsy (Scardino, 1989).  On the other hand, the 
percentage of men with histologic confirmation of PrCa at autopsy was reported as 80% among 
men 70 years of age and older (Breslow, 1977).  This is a 167% increase among men 50 years 
of age and older compared to those 70 years of age and older.   AA men are twice as likely to 
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be diagnosed with PrCa before age 50 compared to all race/ethnic groups (SEER FastStats, 
2012).  Table 3 shows the age-adjusted PrCa incidence rates by age at diagnosis among men 
in the SEER 18 geographic regions. 
Table 3.  Age-Adjusted SEER PrCa Incidence Rates* by Age at Diagnosis, 2009 (SEER 18). 
  Age at Diagnosis 
Race/Ethnicity <50 50-64 65-74 75+ 
All Races 6.14 311.56 853.90 620.01 
Asian 1.53 130.02 477.48 424.98 
Black 14.34 551.17 1278.56 835.35 
Hispanic 3.23 210.84 745.22 566.85 
White 5.21 289.38 804.00 574.57 
*per 100,000 and age adjusted to the 2000 US Std Population 
 In the study conducted by Shavers et al utilizing SEER-Medicare linked data, the results 
indicate that AA men were younger at diagnosis compared to White Hispanic and White Non-
Hispanic men with a mean age at diagnosis of 73.6 years, 74.4 years and 74.4 years, 
respectively, (p-value <0.0001) (Shavers et al, 2004).  The age at PrCa diagnosis is considered 
to be an important clinical factor because age at time of diagnosis has been shown to influence 
treatment options (Stangelberger et al, 2008).   
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 When comparing the overall first course of treatment modalities received using data from 
the National Cancer Data Base (NCDB), men 18-64 years of age were more likely to receive 
surgery (57%) compared to radiation or expectant management, while men 65-74 years of age 
were more likely to receive radiation (42%) compared to surgery or expectant management and 
men 75 years of age and older were more likely to receive expectant management (57%) 
compared to surgery or radiation (Siegel et al, 2012). 
Family History (Hx) of Cancer or PrCa 
Spitz and colleagues conducted a hospital based case control study with approximately 
800 age-matched PrCa cases and controls (Spitz et al, 1991).  The patients were administered 
a risk factor questionnaire and the risk of developing PrCa increased 3 fold among men with a 
brother who had PrCa (Spitz et al, 1991).  Steinberg and team had similar results after 
conducting a case control study.  They found that the cases were significantly more likely to 
have a father or brother diagnosed with PrCa compared to the controls and the risk of a male 
developing PrCa increased as the number of first degree relatives diagnosed with PrCa 
increased (Steinberg et al, 1990).  Likewise, Hayes and colleagues found similar results among 
AA and White men living in Atlanta, Detroit and New Jersey.  The authors concluded there was 
a significant 3 fold increased risk of developing PrCa with a family history of PrCa among a first 
degree relative, OR=3.2, 95%CI (2.0-5.0) (Hayes et al, 1995).  In addition, the risk of developing 
PrCa significantly increased 5 fold if a male had a brother with a history of PrCa, OR=5.3, 
95%CI (2.3-12.5) (Hayes et al, 1995).   
Gronberg and colleagues alluded to familial clustering of PrCa after evaluating over 90 
families that had 3 or more first degree relatives diagnosed with PrCa (Gronberg, et al 1997).  
The results of the study indicate a hereditary linkage of PrCa; however, the primary limitation of 
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the study was no documentation in the manuscript that the study evaluated high risk groups 
such as AA men (Gronberg, et al 1997). 
Approximately 90 North American and Swedish families having a minimum of 3 first 
degree relative diagnosed with PrCa were evaluated and the authors concluded there is a 
hereditary linkage of PrCa on chromosome 1 with the men in the families having an age at 
diagnosis of PrCa less than 65 years of age (Gronberg et al, 1997).  One of the major limitations 
of this study was no discussion that AA families were included in the study population. Yeager 
and team identified chromosome 8q24 as being associated with PrCa risk in a genome-wide 
association study (GWAS) (Yeager et al, 2007).  In addition, Thomas and colleagues from the 
same previous GWAS study group identified PrCa cases and controls by testing ~27,000 single 
nucleotide polymorphism (SNPs) (Thomas et al, 2008).  The authors suggest that the 3 
significant loci identified on 2 SNPs may be used to identify high risk PrCA patients (Thomas et 
al, 2008).  One limitation of this study is that AA men were not represented in the study 
population. 
In summary, men with a family history of PrCa, especially those with an affected first 
degree relative have an increased risk of developing PrCa.  Also, approximately 35 SNPs have 
been validated to be associated with PrCa, explaining 25% of the genetic risk associated with 
PrCa (Aly et al, 2011).  However, genetics does not solely explain why AA men are at a higher 
risk of developing PrCa compared to White, Hispanic or Asian men.   
Race and Ethnicity 
AA men have a prostate specific incidence rate that is 1.6 times higher and 1.9 times 
higher compared to White men, and Hispanic men, respectively (Howlader et al, 2011).  The 
prostate specific mortality rates show the greatest increase when comparing AA men to White 
men (2.5 times higher) and Hispanic men (3 times higher) (Table 4).   
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Table 4.  Summary of SEER Cancer and PrCa Incidence and Mortality Rates by Race and 
Ethnicity per 100,000 men in the U.S. 
 Cancer 
Incidence 
Rate* 
PrCa 
Incidence 
Rate 
Cancer 
Mortality 
Rate* 
PrCa 
Mortality 
Rate* 
Race/Ethnicity Male Male Male Male 
All Races 541.0  154. 222.4  23.6  
Black 626.1  236.0  296.5  53.1  
Hispanic 360.2  125.9  150.5  17.8  
White 543.6  146.9  222.5  21.7 
Source: SEER, 2011 
*All cancers included 
**Compared to Black men 
 
In addition to the differences in PrCa incidence and mortality by race and ethnicity, the 
health disparity is further defined when considering stage at diagnosis. Table 5 below shows 
that AA and Hispanic men have an overall higher incidence of being diagnosed with regional or 
distant PrCa compared to White men (SEER FastStats, 2012).  In essence, this indicates that 
AA and Hispanic men are more likely to be diagnosed with PrCa at a stage where the cancer 
has spread beyond the prostate to other areas of the body such as the lymph nodes and bone.   
Table 5.  SEER PrCa Incidence by Summary Stage at Diagnosis and Race/Ethnicity, per 
100,000 men in the U.S.*                
 SEER Summary Stage at Diagnosis 
Race/Ethnicity Local Regional Distant 
All Races 53.4  24.2  15.0  
Black ** 50.8  24.9  17.8  
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Table 5 (Continued) 
Hispanic^ 49.9  25.8  18.0  
White** 53.7  24.2  14.7  
Source: SEER FastStats, 2012 
*2000-2009 
^Include all races 
**Includes Hispanics 
 
When evaluating race/ethnic differences and PrCa treatment patterns, Polednak and 
Flannery conducted a study to evaluate treatment differences among Black and White patients 
diagnosed with PrCa using the Connecticut Cancer Registry SEER Database (Polednak and 
Flannery, 1992).    The authors determined that Black patients with advanced stage disease 
were significantly less likely to receive surgery only (prostatectomy) compared to Whites, 4.7% 
versus 0% respectively, p-value=0.009 (Polednak and Flannery, 1992).  For all other treatment 
options there were no significant differences among Blacks and Whites.  On the other hand, 
Shavers and colleagues conducted a study using SEER-Medicare linked data and determined 
that AA and Hispanic men are significantly more likely to receive watchful waiting compared to 
White men, adjusted OR (AA) = 1.3, 95%CI (1.1, 1.4) versus adjusted OR (Hispanic) = 1.2, 95% 
CI (1.03,1.4) (Shavers et al, 2004).  The authors defined watchful waiting as not receiving any 
type of first course of treatment (no documentation that radiation, surgery or hormone treatment 
was administered within the first 6 months after diagnosis) (Shavers et al, 2004).  One of the 
major limitations of this study is that the patients included in the study had to be eligible for 
Medicare (age 65 years of age and older).  AA men are twice as likely to be diagnosed with 
PrCa before the age of 50.  The strengths of this study were that the authors were able to 
evaluate the presence or absence of co-morbidities using the claims data from Medicare and 
they were able to adjust for education and income status.  Similarly, Mettlin and colleagues 
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analyzed data from the National Cancer Data Base (NCDB) and it is consistent with other data 
published by Polednak and Shavers in that AA men are more likely to receive no treatment 
(29.1% versus 23.9%) and less likely to receive radiation therapy (28.5% versus 28.8%) and 
radical prostatectomy (22.3% versus 29.1%) compared to Whites (Mettlin et al, 1997).  
Cooperberg and colleagues examined 36 Urologic clinical sites across the U.S. and determined 
that AA men were less likely to receive no treatment (6.2% versus 6.9%) and surgery (44.5% 
versus 50.7%) while they were more likely to receive radiation (26.0% versus 24.8%) 
(brachytherapy or external beam) (Cooperberg et al, 2010).  The addition to this study that the 
aforementioned studies did not evaluate is the receipt of cryosurgery.  The results of the study 
indicate that AA men were less likely to receive cryosurgery compared to White men 
(Cooperberg et al, 2010).  In 2009, Xiao and colleagues determined that NHW men diagnosed 
with localized PrCa were more likely to receive brachy-monotherapy compared to AA men (Xiao 
et al, 2009).  In addition, Xiao and team evaluated an appropriate treatment group 
categorization for PrCa patients using FCDS data and determined that treatment received was 
significantly associated with race (p<0.0001), stage (p<0.0001), and age (p<0.0001) (Xiao et al, 
2013).   The recommended treatment categories were adapted in this study and discussed in 
detail in Chapter 3.  Table 6 compares the results of the studies on the receipt of no treatment, 
radiation and surgery by race/ethnicity. 
Table 6.  Comparison of Results for Treatment Received by Race/Ethnicity 
   Treatment Modality 
Manuscript 
Study 
Sample 
Size 
Race/Ethnicity No Treatment Radiation Surgery 
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Table 6 (Continued) 
Polednak and 
Flannery, 1992 
(Conn State CR) 
4,621 
(5.69% 
AA) 
AA versus W Localized 
9.8% vs 10.2% 
p-value=0.986 
Localized 
15.8% vs 
13.5% 
p-value=0.541 
Localized 
6.8% vs 10.8% 
p-value=0.182 
Mettlin et al, 
1997 
(ACoS, NCDB) 
251,416 
(9.95% 
AA) 
AA versus W 29.1% vs 23.9% 28.5% vs 
28.8% 
22.3% vs 
29.1% 
Shavers et al, 
2004 
(SEER-
Medicare) 
24,974 
(10% AA) 
AA versus W Adjusted OR = 
1.3, 95% CI (1.2, 
1.6) 
NA NA 
Underwood et 
al, 2004 (SEER) 
142,340 AA versus W Localized and 
Regional  
NA 
Localized and 
Regional  
(external 
beam) 
26.5% vs 
23.9% 
Localized and 
Regional  
30.6% vs 
35.4% 
Xiao et al, 2009 104,050 
(9.4% AA) 
AA versus W Localized 
12.8% vs 10.8% 
Localized 
25.3% vs 
26.6% 
Localized 
33.3% vs 
32.7% 
Cooperberg et 
al, 2010 
(CaPSURE, 
40 urology 
practices) 
11,892 
(10.35% 
AA) 
AA versus W 6.2% vs 6.9% 26.0% vs 
24.75% 
44.5% vs 
50.7% 
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Table 6 (Continued) 
Xiao et al, 2013 
(FCDS) 
60,497 
(11.9% 
AA) 
AA versus W No definitive tx 
14.94% vs 
13.09% 
20.69% vs 
23.77% 
40.57% vs 
40.61% 
AA = African American 
W = White 
 
Mettlin and colleagues state that “race related variations in PrCa treatment patterns are 
poorly understood” (Mettlin et al, 1997).  In addition, AA men represent a high risk population 
disproportionately affected by this preventable disease and there is very little known about PrCa 
and treatment patterns among AA men in the State of Florida. Hence, this study focused on 
examining the race/ethnic differences in PrCa treatment patterns among newly diagnosed men 
in Florida diagnosed with PrCa.    
Diet and Obesity 
Pienta and Esper determined, after an analysis of the literature and SEER data, that the 
most dominant PrCa risk factor is dietary fat (Pienta and Esper, 1993).  In addition, using data 
from the prospective cohort of participants in the Health Professionals Follow-up Study, 
Giovannucci and colleagues examined the association between the consumption of dietary fat 
and advanced stage PrCa and concluded that men who had a high consumption of red meat 
had a significant 3 fold increased risk of developing advanced stage PrCa compared to those 
with low consumption of red meat (Giovannucci, 1993).  Rodriguez and colleagues evaluated 
the consumption of red meat among AA and White men in the Cancer Prevention Study II 
(Rodriguez et al, 2006).  The results of the study indicate that AA men were more likely to 
consume more poultry and processed meat (bacon, hot dogs and sausage) and less likely to 
consume unprocessed meat  compared to White men (Rodriguez et al, 2006).  Consumption of 
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processed red meat was significantly associated with a higher incidence of PrCa among the AA 
men, RR=2.7; 95%CI (1.3-5.3) compared to White men (Rodriguez et al, 2006).  Similarly, 
Whittemore and colleagues conducted a case control study among men in the US and Canada 
and determined that the total fat intake was significantly associated with an increased risk of 
developing PrCa among AA, White and Asian men (Whittemore, 1995).  On the other hand, 
Cohen and colleagues found that a high consumption of fruits and vegetables significantly 
reduced the risk of developing PrCa in a case control study among men less than 65 years of 
age (Cohen et al, 2000).  In contrast, Mills and team did not find any significant association 
between the consumption of animal meat and PrCa after adjusting for the consumption of fruits 
and vegetables (Mills et al, 1989); however, it is important to note that the study population 
consisted of males in the Seventh-Day Adventist denomination and consumption of pork is not 
recommended and considered a dietary restriction (Mills et al, 1989).  In addition, Hsing 
conducted a prospective cohort study among males of the Lutheran Brotherhood Insurance 
Society and determined that there was no association between meat, dairy consumption or 
vegetables and PrCa (Hsing et al, 1990).  Severson and colleagues conducted a study among 
Japanese men and their risk of PrCa along with dietary practices utilizing a food frequency 
questionnaire (Severson, 1989).  The results of the study indicate that there was a significant 
increased risk of developing PrCa among those who consumed bread 2 to 4 times per week (3-
fold increased risk), eggs 2 to 4 times per week (2-fold increase risk) and seaweed 5 or more 
times per week (2-fold increased risk) (Severson, 1989).   
In a double blind cancer prevention trial that included approximately 1,000 men who 
were randomized to consume the dietary supplement selenium (Se) or a placebo, the results of 
the study indicate that the incidence of PrCa  was significantly lower in the Se group compared 
to the placebo group, Relative Risk (RR) = 0.37, p=0.002 (Clark, 1998).  Approximately 1,900 
men from the Physicians’ Health Study were evaluated in a nested case control study to 
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examine the risk of PrCa and lycopene levels (Gann, 1999).   The authors concluded that the 
consumption of lycopenes reduced the risk of developing PrCa and provided several reasons 
why this is biologically plausible (Gann, 1999).  
Murphy and colleagues evaluated the association of vitamin D deficiency and prostate 
cancer among ~700 AA and White men in Chicago (Murphy et al, 2014).  The results of the 
study indicate that vitamin D deficiency may be used to predict aggressive or advanced prostate 
cancer versus prostate cancer diagnosis because the authors collected the serum to measure 
the vitamin D at the time near the first prostate biopsy (Murphy et al, 2014).  AA men comprised 
41% of the study population and they were less likely to have a negative initial prostate biopsy 
compared to White men, 37% versus 41%, respectively (Murphy et al, 2014).  Additional studies 
are needed in this area, especially to compare men in southern states to men in northern states 
since vitamin D is derived from sunlight.  
Regarding obesity, Snowdon and colleagues conducted a study on diet, obesity and 
PrCa among Seventh-Day Adventist men and determined that the risk of PrCa increased 2-fold 
among those who were overweight and a 4 fold increase risk of developing PrCa was obtained 
among those who consumed animal products (Snowdon, 1984).  A primary limitation of this 
study is that the study only included white males, so the results were not generalizable to men 
in other race/ethnic groups. 
In summary, diet and obesity are modifiable risk factors and the current literature 
examining the association between PrCa and diet is not consistent and further evaluation is 
needed, especially among diverse populations. 
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Tobacco and Alcohol 
 Hiatt and colleagues determined that smoking ≥1 pack of cigarettes/day was significantly 
associated with an increased risk of PrCa among members of a healthcare plan in California, 
adjusted RR = 1.9, 95%CI (1.2, 3.1).  Hsing and team evaluated tobacco use among the 
Lutheran Brotherhood Cohort and concluded that men who ever used cigarettes, RR = 1.8, 
95%CI (1.1, 2.9) or ever used smokeless tobacco, RR = 2.1, 95%CI (1.1,4.1) had a significant 
increased risk of developing PrCa (Hsing et al, 1990). 
Dennis conducted a meta-analysis of 33 cohort and case control studies and concluded 
that there was no association between PrCa and alcohol or beer consumption (Dennis, 2000).  
Similarly, Hiatt and team found no association between alcohol consumption and risk of PrCa 
among men in California among members of a healthcare plan (Hiatt et al, 1994).  On the other 
hand, Jain and colleagues evaluated alcohol, beer, wine, coffee and liquor consumption among 
Canadian men in a case control study and determined that 10 or more beers consumed per 
day, OR=0.68, 95%CI (0.49,0.94) or consuming 1-9 glasses of wine per day, OR=0.77, 95%CI 
(0.60-0.99) both had a significant protective association with PrCa while there was no significant 
association with alcohol or any of the other beverages (Jain et al, 1998).  Hayes and colleagues 
evaluated the association of alcohol consumption and PrCa among AA and White men in a 
multi-center case control study and concluded that AA men who were heavy alcohol drinkers 
(consumed ≥57 drinks/week) had a 2 fold significant increased risk of having PrCa compared to 
never drinkers, OR=1.8, 95%CI(1.1,3.0) (Hayes et al, 1996).  This same trend was observed in 
White men (Hayes et al, 1996). 
Like diet and obesity, tobacco use is a modifiable risk factor that has the potential of 
increasing the risk of PrCa.  The literature does not consistently show a positive relationship 
between PrCa and alcohol use.  Alcohol, beer and the consumption of other beverages are 
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modifiable risk factors that need further investigation especially among high risk populations 
affected by PrCa.  In addition, studies focusing on the psychosocial aspects of why alcohol 
consumption is elevated or not among the high risk population will add an additional layer of 
knowledge surrounding the association of alcohol and PrCa risk.  
Socioeconomic status 
Bennett and colleagues evaluated 212 men with low income status using the Rapid 
Estimate of Adult Literacy in Medicine (REALM) reading screening test and it was determined 
that AA men with a low income status were more likely to have a less than 6th grade reading 
level (Bennett et al, 1998).  Even after adjusting for reading level, geographic U.S. location, and 
age, race was not significantly associated with low income men having advanced PrCa.  The 
results of this study indicate that income and reading level are not associated with AA men 
having an increased risk of developing PrCa.  The primary limitation of this study is the low 
number of AA men included in the study (n=109).  Similarly, the study conducted by Ward and 
colleagues indicate that American Indian/Alaska Native and AAs have a higher percentage with 
income below the poverty level, 27% and 24%, respectively, compared to Non-Hispanic Whites 
with 8% (Ward et al, 2004).  In addition, 31% and 17% of Hispanics and AAs, respectively, have 
no regular source of medical care compared to 14% of Non-Hispanic Whites (Ward et al, 2004).  
The highest percentage of those under 65 years of age with no healthcare coverage was seen 
among Hispanics, 35%, and American Indian/Alaska Native, 33% (Ward et al, 2004). 
Roetzheim and team determined that insurance status and race are associated with 
PrCa stage at diagnosis (Roetzheim, 1999) where AA men who had non-private insurance or 
those who did not have any insurance were more likely to be diagnosed with advanced stage 
cancer (Roetzheim, 1999).  The lack of health insurance has been described as being a 
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‘structural barrier’ in the ability of AA men seeking appropriate early detection and cancer 
treatment (Ward et al, 2004). 
More research is needed, especially among studies with an adequate representation of 
AA men, in the area of socioeconomic status and the risk of PrCa because the literature does 
not consistently show the same relationship between PrCa risk as it relate to education, health 
insurance status and race.    
Vasectomy 
Giovannucci conducted a cohort study among men 40-75 years of age, enrolled on the 
Health Professional Follow-up Study who were cancer free and had a vasectomy (Giovannucci, 
1999).  The results of the study indicate that men with a vasectomy had  a statistically significant 
increased risk of developing PrCa compared to men without a vasectomy, age-adjusted relative 
risk (AARR) = 1.66, p-value =0.0004 (Giovannucci, 1999).  In addition, the AARR of developing 
PrCa significantly increased as the time from the date of the vasectomy increased (Giovannucci, 
1999).  On the other hand, Cox and colleagues found no statistically significant increased risk of 
developing PrCa after a vasectomy in a case control study (Cox, 2002).  Based on the current 
literature there is no consensus on the risk of developing PrCa after a vasectomy and additional 
research is needed in order to understand this association. 
Prostatitis 
 Sarma and team conducted a case control study to evaluate the risk of PrCa and 
prostatitis and concluded that AA men who reported having prostatitis had a 5 fold significant 
increased risk of having PrCa, adjusted OR = 4.93, 95%CI (2.79-8.74) (Sarma et al, 2006).  In 
addition, a meta-analysis was conducted by Dennis and team and the results of the study 
concluded that men with a history of prostatitis had significant increased odds of having PrCa 
35 
 
(Dennis et al, 2002).  Furthermore, Nelson and team indicated that inflammation of the prostate 
gland is a precursor and initiates the carcinogenic process (Nelson et al, 2004).  Likewise, 
Roberts and team conducted a matched case control study among Minnesota residents and 
concluded that cases with a confirmed history of acute prostatitis were significantly more likely 
to be diagnosed with PrCa compared to the controls, OR=2.5, 95% CI (1.3-4.7)  (Roberts et al, 
2004).  The value added for this study is that the authors calculated the time from the last 
episode of prostatitis diagnosis to the time of PrCa diagnosis and determined there was an 
average of 12 years between this time; however, the time period was not statistically significant 
(Roberts et al, 2004).   
In summary, since prostatitis has been shown to increase the PSA level, Potts 
recommend routine testing to determine the presence or absence of inflammation before 
performing a biopsy (Potts, 2000).  If there is evidence of inflammation, antibiotics are often 
recommended followed by subsequent screening PSA tests (Potts, 2000).  The biologic 
plausibility or the role of pathogenesis for prostatitis increasing the PSA level is that the white 
blood cell count is higher than normal due to the presence of inflammation inside the body 
(Neal, 1992). 
Sexually Transmitted Infections (STI) 
 Taylor and colleagues completed a meta-analysis and concluded that men with a history 
of any sexually transmitted disease/infection have a statistically significant increased risk of 
developing PrCa, OR=1.48, 95% CI (1.26, 1.73) (Taylor et al, 2005).  The sexually transmitted 
infections are applicable to gonorrhea, syphilis, chlamydia, herpes and human papilloma virus 
(HPV).  Hayes and team evaluated the same aforementioned STIs in a case control study; 
however, AA men were included in the study representing 51% of the men interviewed (Hayes 
et al, 2000).  AA men were more likely than White men to report a history of having a STI and 
the risk of PrCa was significantly increased when men reported a history of having both syphilis 
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and gonorrhea (Hayes et al, 2000).  In addition, AA men who reported having 3 or more 
occurrences of gonorrhea had a 3 fold increased risk of having PrCa compared to those who 
never had gonorrhea, OR=3.5, 95%CI (1.4-8.3) (Hayes et al, 2000).  Likewise, Sarma and 
colleagues had similar results from a case control study, where AA men who reported having a 
history of gonorrhea having a significant increased risk of PrCa, after adjusting for various 
potential confounders, adjusted OR=1.78, 95%CI (1.13-2.79) (Sarma et al, 2006).  A study 
conducted among men in Cuba yielded similar results.  Cuban men with a history of a STI had a 
significant increased risk of having PrCa, OR=1.7, 95%CI (1.1, 2.5) (Fernandez et al, 2005). 
 In summary, the literature shows that men with a personal history of having a STI have 
an increased risk of developing PrCa. The biologic plausibility of this association is due to the 
STI leading to prostatitis or inflammation of the prostate and the inflammation initiating 
carcinogenesis (Taylor et al, 2005). 
Occupation 
Krstev and colleagues conducted a case control study to evaluate the risk of PrCa and 
occupation/industry using death certificates and determined that men in both blue collar and 
white collar occupations had an excess risk of PrCa (Krstev, 1998).  In addition to evaluating 
occupation, Hsing and colleagues evaluated physical activity among newly diagnosed PrCa 
cases reported to the Cancer Registry in urban Shanghai and concluded that men in 
occupations associated with obtaining less physical activity have a higher risk of developing 
PrCa (Hsing et al, 1994).  It is important to note that the association was not statistically 
significant.   
Among men living in Hawaii with Japanese ancestry, Severson and team, conducted a 
case control study and compared to men in an unskilled manual occupation, men in a skilled 
manual occupation had an increased risk of PrCa, RR=1.30, 95%CI (0.83, 2.03) and men in 
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non-manual (managerial) occupations had an increased risk of PrCa, RR=1.24, 95%CI (0.78, 
1.95); however, none of the RRs were statistically significant (Severson et al, 1989).  Similarly, a 
case control study conducted among Italian men concluded that clerical and professional 
workers had an increased risk of PrCa compared to industry or manual workers , adjusted RR = 
1.53, 95%CI (0.83-2.83); however, the association was not statistically significant (Talamini et 
al, 1986).  On the other hand, a case control study evaluating occupation, industry and cancer 
among Canadian men resulted in statistically significant associations between the risk of PrCa 
and water transport workers, railway transport workers, structural erectors, metal product 
fabricators and aircraft manufacturing occupations/industries (Aronson et al, 1996). 
In summary, the literature is showing an overall positive association between 
occupation/industry and the risk of developing PrCa; however, very few occupation/industry 
associations have been shown to be statistically significant (Aronson et al, 1996; Talamini et al, 
1986; Severson et al, 1989).  One of the primary limitations of the literature evaluating 
occupation/industry and the risk of PrCa is a low representation of AA men in the study groups 
which makes it difficult to extrapolate any information specific to this high risk group of men. 
Summary of PrCa Risk Factors 
It is clear that more research is needed in the area of PrCa etiology.  Out of all the 
aforementioned risk factors, Lichtenstein and colleagues indicate that having a family history of 
PrCa explains 40% of PrCa disease risk (Lichtenstein, Holm, et al, 2000).  In terms of modifiable 
risk factors it is important the men focus on the risk factors they can control such as diet, 
exercise, exposure to sexually transmitted infections, tobacco smoking and alcohol 
consumption.   
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Background information on the National Comprehensive Cancer Network (NCCN) 
The vision of NCCN is to “be the world’s leader in defining and advancing high quality, 
high volume cancer care” (www. NCCN.org, 2012 Annual Report).  NCCN is a not for profit 
organization of 25 cancer centers across the U.S. that was created in November 1993 to 
implement standards of cancer care (www.NCCN.org).  Moffitt Cancer Center and Research 
Institute is the only NCCN member institution in the State of Florida.  The complete list of all 25 
NCCN cancer centers is provided in Table 7 below. 
Table 7.  NCCN Participating Cancer Centers 
NCCN Cancer Center Location 
City of Hope Comprehensive Cancer 
Center Los Angeles, California 
Dana Farber/Brigham and Women’s 
Cancer Center, Massachusetts 
General Hospital Cancer Center 
Boston, Massachusetts 
Duke Cancer Institute Durham, North Carolina 
Fox Chase Cancer Center Philadelphia, Pennsylvania 
Huntsman Cancer Institute at the 
University of Utah Salt Lake City, Utah 
Fred Hutchinson Cancer Research 
Center/Seattle Cancer Care Alliance Seattle, Washington 
The Sidney Kimmel Comprehensive 
Cancer Center at Johns Hopkins Baltimore, Maryland 
Robert H. Lurie Comprehensive 
Cancer Center of Northwestern 
University Chicago, Illinois 
Memorial Sloan-Kettering Cancer 
Center New York, New York 
Moffitt Cancer Center Tampa, Florida 
The Ohio State University 
Comprehensive Cancer Center - 
James Cancer Hospital and Solove 
Research Institute Columbus, Ohio 
Roswell Park Cancer Institute Buffalo, New York 
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington 
University School of Medicine St. Louis, Missouri 
St. Jude Children’s Research 
Hospital/The University of 
Tennessee Health Science Center Memphis, Tennessee 
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Table 7 (Continued) 
Stanford Cancer Institute Stanford, California 
University of Alabama at Birmingham 
Comprehensive Cancer Center Birmingham, Alabama 
UCSF Helen Diller Family 
Comprehensive Cancer Center San Francisco, California 
University of Michigan 
Comprehensive Cancer Center Ann Arbor, Michigan 
Fred and Pamela Buffett Cancer 
Center at The Nebraska Medical 
Center Omaha, Nebraska 
Yale Cancer Center/Smilow Cancer 
Hospital New Haven, Connecticut 
Mayo Clinic Cancer Center 
Phoenix/Scottsdale, 
Arizona 
Jacksonville, Florida 
Rochester, Minnesota 
UC San Diego Moores Cancer 
Center La Jolla, California 
University of Colorado Cancer 
Center Aurora, Colorado 
The University of Texas MD 
Anderson Cancer Center Houston, Texas 
Vanderbilt-Ingram Cancer Center Nashville, Tennessee 
  
Source: www.NCCN.org 
In November 1996, the first NCCN Clinical Practice Guidelines in Oncology were created 
and PrCa was included as one of seven cancer sites released with clinical evidence based 
practice guidelines for clinicians to utilize (www.NCCN.org, 2012 Annual Report).   Since the 
first Clinical Practice Guidelines in Oncology were released over 17 years ago, 
updates/changes have been made in order to provide clinicians and patients with 
comprehensive decision-making educational material (www.NCCN.org, 2012 Annual Report).    
As of 2013, the NCCN has created over 50 Clinical Practice Guidelines in Oncology, created 
over 140 algorithms and all of the member cancer centers see ~160,000 new patients per year 
(www.NCCN.org).   The NCCN Clinical Practice Guidelines continuously update evidence 
based clinical recommendations for decisions made in cancer screening, diagnosis and 
treatment (www.NCCN.org, 2012 Annual Report).  The standard of care for patients diagnosed 
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with PrCa, based on NCCN guidelines, depend on various factors such as life expectancy, 
clinical stage, Gleason score (Gleason primary and secondary pattern), the results of bone 
scan, magnetic resonance imaging (MRI) and/or pelvic computed tomography (CT) scan, risk of 
recurrence and expected survival (NCCN Prostate Guidelines v4.2013).   
The primary advantage of utilizing the Clinical Practice Guidelines created by the NCCN 
is that the recommendations are evidence based (www.NCCN.org, 2012 Annual Report).  The 
primary limitation of using the Clinical Practice Guidelines created by the NCCN is that clinicians 
are not required to follow the recommendations; therefore, there may be variation in the way the 
recommendations are implemented in clinical practice.  Secondly, the NCCN recommendations 
are not personalized and may not be applicable to all patients.  For example, 5% of the PrCa 
tumors have a rare histology (Bostwick et al, 1989) and the NCCN clinical treatment guidelines 
target patients diagnosed in the 95% histology group.  
Background Information on the Florida Cancer Data System (FCDS) 
FCDS was created in 1978 based on a Florida Legislature mandate to create a state 
cancer registry and by 1980 the University of Miami started a pilot study to collect data on 
approximately 5,000 cases from Southeast Florida (Dr. Jill MacKinnon presentation at FCDS 
annual conference on 7/25/13).  In early 1980, a total of six hospitals reported cancer cases to 
FCDS and the State of Florida and by the middle of 1981 approximately 1,500 cancer cases 
were reported to FCDS (Dr. Jill MacKinnon presentation at FCDS annual conference on 
7/25/13).  As of July 25, 2013, 244 hospitals, 136 radiation treatment centers, 429 surgery 
centers, 661 pathology centers and 1,334 private physician offices are currently reporting cases 
to FCDS (Dr. Jill MacKinnon presentation at FCDS annual conference on 7/25/13).  Newly 
added in 2012, private physicians that work in the specialty areas of Dermatology, Oncology, 
Urology and Hematology started reporting their cancer cases to FCDS (Dr. Jill MacKinnon 
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presentation at FCDS annual conference on 7/25/13).  With the additional cases being reported, 
the number of yearly FCDS cases is expected to increase over 20% in order to fill the gap with 
cases that have been considered to be underestimated (Dr. Jill MacKinnon presentation at 
FCDS annual conference on 7/25/13).  For example, in a pilot study conducted by FCDS it was 
determined that 29% of the cases were missed because physician offices do not report 
diagnosis and treatment to FCDS (Dr. Jill MacKinnon presentation at FCDS annual conference 
on 7/25/13).  More specifically, it was determined that 15% of the missed cases were 
leukemia/lymphoma cases, 11% of the missed cases were early stage gynecologic and prostate 
cases and 10% were myleodysplastic syndrome (MDS) cases (Dr. Jill MacKinnon presentation 
at FCDS annual conference on 7/25/13).    In June 2012, FCDS started collecting diagnosis and 
treatment information from physician offices such as Florida Cancer Specialists that include 
approximately 150 physicians in 30 counties across the State of Florida utilizing claims data with 
Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System 
(HCPCS) and the International Classification of Diseases, ninth revision (ICD-9) codes to 
identify the cancer diagnoses corresponding to the procedures (Dr. Jill MacKinnon presentation 
at FCDS annual conference on 7/25/13).  As a result of the pilot study an additional 3.7 million 
additional rows of data were added with a 71% match rate at the patient to tumor level (Dr. Jill 
MacKinnon presentation at FCDS annual conference on 7/25/13).  The impact of this limitation 
with the FCDS data on the current study is that this study is not generalizable to patients who 
are diagnosed and treated in State of Florida in a physician’s office.   
The data collected by FCDS is abstracted at the hospital/facility level by Certified Tumor 
Registrars (CTR) and non-CTRs (Michael Thiry presentation at FCDS conference on 7/25/13).  
As of July 2013, there are 461 abstractors with a valid FCDS abstractor code (Michael Thiry 
presentation at FCDS conference on 7/25/13).  Over 190,000 cancer abstracts and 
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approximately 900,000 pathology records were submitted during FY 2013 (July 1st – June 30th) 
(Michael Thiry presentation at FCDS conference on 7/25/13). 
The quality of the FCDS data is evaluated on a quarterly and annual basis at the local 
Cancer Registry hospital level and by FCDS.  At the national level, FCDS has been awarded 
Silver and Gold level certification by the North American Association of Central Cancer 
Registries (NAACCR) for the quality, completeness and timeliness of data that has been 
submitted indicating that FCDS has consistently achieved 90% or higher complete case 
ascertainment (NAACCR website on 8/14/13, http://www.naaccr.org/Certification/Criteria.aspx).  
FCDS has successfully maintained complete case ascertainment of 95% or higher since 1998 
(NAACCR website on 8/14/13, http://www.naaccr.org/Certification/Criteria.aspx).  Certification 
by NAACCR is important because the certification establishes that the data is high quality and 
can be utilized for the purpose of calculating incidence rates (NAACCR website on 
8/14/13, http://www.naaccr.org/Certification/Criteria.aspx). For the past 11 years, data 
representing CY2000 through CY2010, FCDS has consecutively received the NAACCR Gold 
Certification indicating the highest possible NAACCR standard for complete, timely and 
accurate data (see Table 8) (NAACCR website on 
8/14/13, http://www.naaccr.org/Certification/Criteria.aspx). 
 
Table 8.  FCDS NAACCR Certification Levels by Calendar Year 
Calendar Year Gold Silver Certified 
1997     X 
1998   X   
1999   X   
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2000 X     
Table 8 (Continued) 
2001 X   
 2002 X     
2003 X     
2004 X     
2005 X     
2006 X     
2007 X     
2008 X     
2009 X     
2010 X     
 
In terms of responsibility for the quality of the FCDS data, the hospitals/facilities who 
submit the data have multiple data edits that must be satisfied before the abstracted data can 
be electronically submitted to FCDS.  The data edits serve as the first pass in terms of verifying 
the quality of the data.  Additional quality checks are completed by FCDS staff once the 
hospital/facility data is submitted to FCDS.  If there are any questions about a case after it is 
submitted, FCDS contacts the respective facility/hospital, as needed, for additional clarification 
and/or documentation. 
At the hospital/facility level, the treatment data is coded according to the primary site of 
treatment.  For example, if a patient is diagnosed with primary PrCa the primary site of surgery 
can be a radical or total prostatectomy.  In addition to the type of treatment that is administered, 
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the treatment start date and treatment end date are also collected.  The treatment end dates 
may be unknown for some treatment modalities, especially for patients that are undergoing 
hormone, chemotherapy or immunotherapy at the time the case was abstracted.  When FCDS 
receives the data the first course of treatment modalities can be dichotomized into treatment 
modality administered equal yes or treatment modality administered equal no (example: first 
course surgery = yes or first course surgery = no).  The same is true for the other first course of 
treatment modalities such as chemotherapy, radiotherapy, hormone therapy and 
immunotherapy. 
There are changes to the data elements collected over time by FCDS.  Most of this is 
due in part to the changes in how the Cancer Registry data is collected and coded at the 
national level.  For example, Collaborative Staging (CS), a cancer staging guideline system, 
was implemented in 2004 and applies to cases that were diagnosed on or after January 1, 2004 
(cancerstating.org, 2014).  The CS system will no longer be used starting in 2016 and the 
American Joint Committee on Cancer will continue to be used in place of CS 
(cancerstaging.org, 2014).  In addition, as the knowledge of cancer and treatment options have 
enhanced over the years so has the possibilities and available options in coding and 
documenting the cancer occurrences along with the variety of data elements collected that can 
be analyzed in order to better understand the cancer process.  For this study, the time period in 
which there were minimal data element changes, from a clinical perspective, was evaluated.  
The data elements selected and the rationale for selecting the data elements are discussed in 
Chapter 3. 
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CHAPTER THREE: METHODOLOGY 
 
Study Design 
 
The overall goal of this study was to examine the differences in treatment/management 
strategies that were newly diagnosed AA and NHW men in Florida newly diagnosed with 
pathologically-confirmed PrCa.  This study utilized retrospective data collected from cancer 
registries and facilities in the State of Florida and the study design is a retrospective cohort 
study.  A major strength of this study design, which utilized cancer registry data, was that the 
data were collected by trained staff using a standardized format.   
Study Population 
 
The proposed study population consisted of incident PrCa cases that were diagnosed in 
Florida or elsewhere and received all or part of their first course treatment in Florida.  Diagnosis 
of PrCa was defined using the C61.9 International Classification of Diseases for Oncology, Third 
Edition (ICDO-3) code (Fritz et al, 2000).  The treatment modalities of interest include no 
treatment, surgery, radiation, hormone therapy, immunotherapy and chemotherapy.  NH AA and 
NHW men were included in this study analyses. 
 
Data Sources 
This study utilized publicly available data from the FCDS cancer which includes PrCa 
cases from 1982-2012, see Appendix D.  The Florida Department of Health (FL DOH) and 
FCDS are responsible for maintaining the publicly available cancer registry data collected 
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throughout the State of Florida.  FCDS is supported by the Sylvester Comprehensive Cancer 
Center at the University of Miami Miller School of Medicine, the FDOH and the National 
Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention 
(CDC).   
Statistical Analysis Products 
 
The Statistical Analysis Software (SAS) version 9 (SAS Institute, Inc., Cary, NC) and Microsoft 
Excel version 2010 were utilized to perform all analyses. 
 
Inclusion/Exclusion Criteria 
Appendix C details the inclusion/exclusion criteria for the variables of interest included in this 
study and Appendix D detailed the list of variables available for request from FCDS.  The final 
inclusion/exclusion criteria are described in detailed in Appendix M.  The rationale for including 
the data elements identified in the inclusion/exclusion criteria were as follows:  
• Primary site used was C61.9 from the International Classification for Diseases, 
Oncology, Third Edition (ICDO-3) which represents PrCa. 
 
Source: FCDS, Data Acquition Manual, 2013 
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 • Morphology (histology) = adenocarcinoma was selected for analysis because 
adenocarcinomas represent 95% of all PrCa tumors.  The rare PrCa histologic types that 
comprise 5% of PrCa cases, such as mucinous, ductal, neuroendocrine and small cell 
carcinoma was not addressed (Bostwick et al, 1989). 
• Class of case 
o Class of case determines newly diagnosed cases (analytic) versus cases that 
present to a facility with recurrent, progressive or persistent disease (non-
analytic).  The cases of interest in this study were the newly diagnosed (analytic) 
cases.  The analytic cases represent class of case equal to 00 – 22. 
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 Source: FCDS, Data Acquition Manual, 2013 
• Master sequence number = 00 or 01 
o Sequence number determines the number of multiple primary tumors a patient 
has.  The PrCa tumors of interest for this study were the tumors where PrCa was 
the only primary cancer or PrCa was the first of many primary cancers, based on 
FCDS records.   
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 Source: FCDS, Data Acquition Manual, 2013 
• Diagnostic confirmation was determined by selecting cases that had pathologically 
confirmed primary prostate adenocarcinoma cancer.  
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 Source: FCDS, Data Acquition Manual, 2013 
• Cases with age at diagnosis greater than or equal to 18 years of age were included in 
this study. 
• The study population was limited to race equal to AA (Black) or White. 
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 Source: FCDS, Data Acquition Manual, 2013 
• The study population was limited to Spanish/Hispanic Origin equal to Non-Hispanic only. 
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Source: FCDS, Data Acquition Manual, 2013 
• Behavior  
o Confirmed that prostate tumor is malignant in order to exclude any benign 
tumors. 
Study Variables 
• Life expectancy, a derived or calculated variable using the Social Security Administration 
Life Table (see Appendix F). 
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o Life expectancy was the variable of interest and not years of potential life lost in 
order to effectively compare the NCCN Clinical Practice Guidelines over time. 
 
• Treatment modalities 
o Surgery Date 
 
Source: FCDS, Data Acquition Manual, 2013 
o Surgery of primary site 
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Source: FCDS, Data Acquition Manual, 2013 
o Surgery procedure 
 
Source: FCDS, Data Acquition Manual, 2013 
o Reason for no surgery 
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 Source: FCDS, Data Acquition Manual, 2013 
o Chemotherapy 
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 Source: FCDS, Data Acquition Manual, 2013 
 
o Chemotherapy date 
 
Source: FCDS, Data Acquition Manual, 2013 
o Hormone or Endocrine therapy 
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 Source: FCDS, Data Acquition Manual, 2013 
 
Source: FCDS, Data Acquition Manual, 2013 
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o Hormone Date  
 
Source: FCDS, Data Acquition Manual, 2013 
o Radiation Date 
 
Source: FCDS, Data Acquition Manual, 2013 
o Radiation Therapy 
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 Source: FCDS, Data Acquition Manual, 2013 
o Immunotherapy Date 
 
Source: FCDS, Data Acquition Manual, 2013 
o Immunotherapy 
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 Source: FCDS, Data Acquition Manual, 2013 
• Date of last contact or Date of death  
o FCDS passively receives date of death from the National Death Index and the 
Florida Department of Vital Statistics. 
 
Source: FCDS, Data Acquition Manual, 2013 
• Vital status (dead/alive) 
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Source: FCDS, Data Acquition Manual, 2013 
• Tobacco use 
 
 
Source: FCDS, Data Acquition Manual, 2013 
• Marital status 
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 Source: FCDS, Data Acquition Manual, 2013 
• Primary Payer at Diagnosis 
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Source: FCDS, Data Acquition Manual, 2013 
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• Date of diagnosis 
 
 
Source: FCDS, Data Acquition Manual, 2013 
• Cancer status (no evidence of disease versus evidence of disease versus unknown) 
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Source: FCDS, Data Acquition Manual, 2013 
• Grade/Differentiation 
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 Source: FCDS, Data Acquition Manual, 2013 
• County of residence at diagnosis  
• SEER Summary Stage (1997 and 2000) (local versus regional versus distant disease) 
• Collaborative Staging site specific factor 1, PSA lab value (document the highest pre-
biopsy or pre-surg PSA value) 
• Collaborative staging site specific factor 2, PSA lab value category (positive, negative, 
borderline, test not done, unknown) 
• Collaborative staging site specific factor 5 (Gleason’s pattern) 
• Collaborative staging site specific factor 6 (Gleason’s score) 
• Collaborative staging lymph nodes 
Xiao and colleagues created a treatment categorization methodology for PrCa first course of 
treatment modalities in order to achieve an adequate sample size as well as treatment groups 
that are clinically relevant (Xiao et al, 2013).  Using FCDS data, the team had a total of 14 
different treatment categories that were truncated to 8 categories that were mutually exclusive 
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(Xiao et al, 2013). The following 10 treatment categories was adapted from the study by Xiao 
and team and utilized in this study (Xiao et al, 2013):  
• Surgery only 
• Surgery + radiation therapy 
• Surgery + radiation therapy + hormone therapy 
• Surgery + hormone therapy 
• Hormone therapy 
• Radiation therapy 
• Radiation therapy + hormone therapy 
• Other therapy (chemotherapy and/or immunotherapy with surgery) 
• No treatment (watchful waiting = no surgery, hormone therapy, radiation therapy or 
other therapy received within the first 6 months after the month of diagnosis) 
• Active Surveillance (active surveillance = no surgery, hormone therapy radiation 
therapy or other therapy received with the first year after the month of diagnosis, 
starting from 6 months and 1 day so that the time for active surveillance does not 
overlap with the time period for no treatment/watchful waiting) 
 
Statistical Methodology 
 
                                                 Preliminary Analyses 
Based on the aggregate, de-identified data obtained from FCDS in March 2013 there 
were a total of 356,787 PrCa cases.  The only exclusion made on the dataset was primary site 
group = 51 (prostate).  Tables 8, 9, and Appendix E, detail the demographic and clinical 
characteristics of the PrCa cases.  Utilizing previously described data elements from the FCDS, 
the inclusion/exclusion criteria were applied to restrict to the cases of interest, which totaled 
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227,799 PrCa cases (see Appendix F).  Approximately 13% of the PrCa cases were NH AA 
men while 87% were NHW men.   
Hypothesis 1/Aim 1 
 
Hypothesis 1 
There are differences in the treatment patterns between AA men and NHW men newly 
diagnosed with prostate cancer in Florida by stage at diagnosis/tumor grade and age at 
diagnosis. 
Aim 1 
To compare the first course treatment modalities received by newly diagnosed prostate cancer 
patients in Florida between AA and NHW men among men with the same stage at 
diagnosis/tumor grade and age at diagnosis. 
Chi-square tests of statistical independence or Fisher’s exact test was used to determine 
the association between the categorical clinical and demographic variables of interest and 
race/ethnicity, whereas the independent samples t-test was used to evaluate the association 
between race/ethnicity and continuous variables.  The p-values assessed were 2-sided.  The 
adjusted association between race/ethnicity and all of the variables was obtained by completing 
a regression analysis.  Multinominal logistic regression was used to compare the first course of 
treatment modalities between AA and NHW men and to estimate adjusted odds ratio (AORs) 
and 95% confidence interval (CI), which represent race/ethnicity-treatment association, 
adjusting for the variables of demographic and clinical importance.   
In the multinominal regression model, the dependent variable was treatment modality 
(16 levels) and the primary independent variable was race/ethnicity.  No treatment was used as 
the comparison treatment group.  Other independent variables were demographic (age at 
diagnosis) and clinical variables (stage at diagnosis, tumor grade).  The approach to model 
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building was forward selection; however, there were study variables that were clinically 
significant that were kept in the model even if they were not statistically significant.   
 
Hypothesis 2/Aim 2 
Hypothesis 2 
The treatment modalities administered to AA men and NHW men newly diagnosed with PrCa in 
FL may differ from recommended treatment as per NCCN guidelines among men with the same 
stage at diagnosis/tumor grade, age at diagnosis and life expectancy. 
Aim 2 
To determine if the treatment modalities administered to AA men and NHW men differ from the 
treatment recommendations of the NCCN among men with the same stage at diagnosis/tumor 
grade, age at diagnosis and life expectancy. 
In order to adequately compare the recommendations for the treatment modalities from 
NCCN it was important to know the life expectancy of the PrCa patients.  At the time of 
diagnosis, life expectancy was extrapolated using the expectation of life table created by Arias 
(Arias, 2010) and life expectancy was categorized into 3 groups, less than 10 years, between 10 
and 19 years and greater than or equal to 20 years.  The aforementioned life expectancy 
categories were utilized because the NCCN guidelines were based on men that fall into those 
categories.  The treatment modalities adapted by Xiao and team was utilized in order to 
determine adherence to the NCCN recommendations (Xiao et al, 2013). The treatment groups 
were created by Xiao et al based on clinical relevance for patients diagnosed with PrCa and 
having an adequate sample size. 
One of the limitations noted with the methodology and study design is that men may die 
from other disease related co-morbidities (competing risk), such as diabetes, hypertension or 
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heart disease and not PrCa or before the PrCa causes any detectable symptoms (Judy Bonner 
and Mayra Espino presentation at FCDS annual conference on July 26, 2013).  Secondly, once 
the dataset is requested from FCDS it is a static dataset.  If a patient died after the dataset was 
released this information was not considered in this study. 
The University of South Florida Institutional Review Board (USF IRB) approved this 
study (IRB# Pro00016727).  In addition, approval was also obtained from the Florida 
Department of Health, Bureau of Epidemiology and FCDS to utilize the Limited CD with the 
inclusion of vital status, date of last contact, date of last contact flag and passive follow-up date 
of death data elements from the full confidential CD.  
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CHAPTER FOUR: RESULTS 
Part I. Hypothesis 1/Aim 1 
Hypothesis 1 
There are differences in the treatment patterns between AA men and NHW men newly 
diagnosed with PrCa in Florida by stage at diagnosis/tumor grade and age at diagnosis. 
Aim 1 
To compare the first course treatment modalities received by newly diagnosed prostate cancer 
patients in Florida between AA and NHW men among men with the same stage at 
diagnosis/tumor grade and age at diagnosis. 
Descriptive Statistics 
The study population consisted of 244,449 NHW and AA men in Florida histologically 
diagnosed with primary prostate cancer between calendar years 1982 to 2012.  NHW men 
represented 87.5% of the study population while AA men represented 12.5% of the study 
population.  Statistically significant race/ethnic differences exist by marital status (p<0.0001), 
vital status (p<0.0001), year of diagnosis (p<0.0001), stage at diagnosis (p<0.0001), age at 
diagnosis (p<0.0001), health insurance payer (p<0.0001), tumor grade (p<0.0001), no first 
course treatment (p<0.0001), surgery only or surgery in combination with other treatment 
modalities (p<0.0001), radiation therapy only (p<0.0001), surgery and radiation (p<0.0001), 
hormone therapy or hormone therapy in combination with other treatment modalities 
(p<0.0001), radiation and hormone therapy (p<0.0001), surgery/hormone/radiation therapy 
(p=0.005), endocrine therapy only or endocrine therapy in combination with other treatment 
modalities (p<0.0001) and other therapy (p<0.0001) (see Appendix N, Table 11).  More 
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specifically, AA men were more likely to be diagnosed with distant disease at diagnosis (8% vs. 
5%), more likely to be diagnosed less than 50 years of age (4% vs. 1%, p<0.0001), more likely 
to be diagnosed 50-64 years of age (41% vs. 25%, p<0.0001), more likely to have no health 
insurance (3% vs. 1%, p<0.0001), more likely to have a higher tumor grade (grade 3, 36% vs. 
30%, p<0.0001), more likely to have never been married (16% vs. 6%, p<0.0001) and more 
likely to be alive (63% vs. 53%, p<0.0001) compared to NHW men.   
Results by Stage at Diagnosis 
Stratifying the results by race/ethnicity and stage at diagnosis, AA men were, on 
average, consistently diagnosed with prostate cancer 4 years younger compared to NHW men 
across all stages at diagnosis, localized disease (65 versus 69 years), regional disease (63 
versus 67 years), and distant disease (69 versus 73 years) (See Appendix N, Table 12).  In 
addition, AA men have a wider age range at diagnosis (29-105 versus 32-104) compared to 
NHW men.  AA men were more likely to have never been married compared to NHW men with 
AA men with distant disease having the highest percentage of those who have never been 
married (20.38%).  Regarding health insurance, AA men were more likely to have no health 
insurance across all stages of disease compared to NHW men.  On the other hand, NHW men 
were more likely to be diagnosed with tumor grade 4 across all stages of disease compared to 
AA men while AA men were more likely to be diagnosed with tumor grades 1, 2 and 3 across all 
stages of disease compared to NHW men (See Appendix N, Table 12).   
After adjusting for potential clinical and demographic confounders, the results by stage 
at diagnosis indicate that AA men were significantly less likely to receive surgery only or surgery 
in combination with other treatment modalities compared to NHW men.  This result was 
consistent across all stages of disease, localized (adjusted OR=0.66, 95% CI (0.63, 0.68), 
p<0.0001), regional (adjusted OR=0.63, 95% CI (0.57, 0.71), p<0.0001) and distant (adjusted 
OR=0.50, 95% CI (0.34, 0.75), p<0.0007) (See Appendix N, Table 13).  Among men with distant 
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disease one would expect them to receive chemotherapy, hormone therapy or immunotherapy 
and the results of this study indicate that AA men with distant disease were significantly more 
likely to receive other therapy which include chemotherapy only, immunotherapy only, endocrine 
therapy only and other therapy only (adjusted OR=1.21, 95% CI (1.04, 1.40), p=0.01) compared 
to NHW men.  On the other hand, AA men with distant disease were less likely to receive 
surgery in combination with other treatment modalities (adjusted OR=0.50, 95% CI (0.34, 0.75), 
p<0.0007) or radiation and hormone therapy combined (adjusted OR=0.86, 95% CI (0.76, 0.98), 
p=0.03) compared to NHW men.  Appendix N, Table 14 summarizes the treatment patterns that 
are statistically significant by stage at diagnosis.    
Results for Treatment Modality 
Regarding the receipt of treatment, AA men were less likely to receive no first course 
treatment (23% vs. 29%, p<0.0001) or radiation therapy only (27% vs. 29%, p<0.0001) 
compared to NHW men.  AA men with localized or regional disease at diagnosis were more 
likely to receive no first course treatment while there were no significant differences among AA 
and NHW men with distant disease.  In addition, AA men were more likely to receive hormone 
therapy only for localized disease and less likely to receive hormone therapy only for distant 
disease compared to NHW men.  Although AA men were less likely to receive radiation therapy 
only for regional disease there were no significant differences in the administration of radiation 
therapy only among those with localized or distant disease compared to NHW men.  For 
treatment combination therapy, AA men were more likely to receive radiation and hormone 
combination therapy for localized (16% vs 15%) or regional disease (10% vs 9%) compared to 
NHW men. 
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Results by Tumor Grade 
There were no statistically significant differences in treatment for tumor grade 4 by 
race/ethnicity (See Appendix N, Table 15).  Similar to the results stratified by stage at diagnosis, 
AA men were less likely to receive surgery compared to NHW men for tumor grade 1 (adjusted 
OR=0.55, 95% CI (0.46, 0.67), p<0.0001), tumor grade 2 (adjusted OR=0.68, 95% CI (0.65, 
0.71), p<0.0001) and tumor grade 3 (adjusted OR=0.57, 95% CI (0.53, 0.60), p<0.0001) 
(Appendix N, Table 16).  By tumor grade, AA men were more likely to receive hormone therapy 
only or hormone therapy in combination with other treatment modalities compared to NHW men 
for tumor grade 1 (adjusted OR=1.23, 95% CI (1.09, 1.38), p=0.0007), tumor grade 2 (adjusted 
OR=1.22, 95% CI (1.17, 1.27), p<0.0001) and tumor grade 3 (adjusted OR=1.20, 95% CI (1.15, 
1.26), p<0.0001).  In addition, AA men were more likely to receive radiation only for tumor grade 
1 and tumor grade 2; however, AA men were less likely to receive radiation therapy only for 
tumor grade 3 (adjusted OR=0.94, 95% CI (0.90, 0.99), p=0.03).  However, AA men with tumor 
grade 3 were more likely to receive no first course treatment (adjusted OR=1.27, 95% CI (1.20, 
1.35), p<0.0001).  This contradicts previous research indicating that men diagnosed with 
advanced prostate cancer were commonly administered hormone therapy, chemotherapy or 
immunotherapy (Mettlin et al, 1997; Polednak and Flannery, 1992); Shavers et al, 2004; 
Cooperberg et al, 2010; Albertsen et al, 1998).  
Results by Age at Diagnosis 
Evaluating age at diagnosis and treatment patterns stratified by race/ethnicity, AA men 
across all age groups were less likely to receive surgery in combination with other treatment 
modalities (age <50 (adjusted OR=0.71, 95% CI (0.61, 0.82), p<0.0001, age 50-64 (adjusted 
OR=0.65, 95% CI (0.62,0.68), p<0.0001, age 65-74 (adjusted OR=0.62, 95% CI (0.58,0.65), 
p<0.0001, age 75+ (adjusted OR= 0.56, 95% CI (0.44, 0.72), p<0.0001, compared to NHW men 
(See Appendix N, Table 17 and Table 18).  On the other hand, AA men were more likely to 
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receive hormone therapy and/or radiation therapy in combination with other treatment modalities 
across all age groups compared to NHW men.  In addition, AA men age 50-64 (adjusted 
OR=1.09, 95% CI (1.04-1.15), p=0.0012) and age 75+ (adjusted OR=1.19, 95% CI (1.11, 1.27), 
p<0.0001) were more likely to receive no first course treatment compared to NHW men. 
Summary of Hypothesis 1/Aim 1 
Statistically significant race/ethnic differences exist by marital status, vital status, year of 
diagnosis, stage at diagnosis, age at diagnosis, health insurance payer, tumor grade, no first 
course treatment, surgery only or surgery in combination with other treatment modalities, 
radiation therapy only, surgery and radiation, hormone therapy or hormone therapy in 
combination with other treatment modalities, radiation and hormone therapy, 
surgery/hormone/radiation therapy, endocrine therapy only or endocrine therapy in combination 
with other treatment modalities and other therapy.  Regarding age at diagnosis, AA men were 
diagnosed with prostate cancer at an earlier age and have a wider age range compared to NHW 
men. 
The take home message for research question one is that regardless of age at 
diagnosis, stage at diagnosis, or tumor grade, AA men were significantly less likely to receive 
surgery only or surgery in combination with other treatment modalities compared to NHW men.  
On the other hand, AA men were significantly more likely to receive radiation therapy only, 
radiation therapy in combination with hormone therapy or hormone therapy only compared to 
NHW men. 
Reason for No Surgery 
To better understand why AA men were less likely to receive surgery as part of first 
course treatment compared to NHW men, the reason for no surgery variable was evaluated.  
The overall reason for no surgery indicate that 49.4% of men received surgery as part of first 
course treatment while 48.9% of men did not have surgery planned as part of first course of 
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treatment (Figure 2 below).  The remaining 1.7% of cases did not receive surgery as part of first 
course of treatment because surgery was contraindicated, the patient died before surgery could 
be performed, patient refused surgery, no reason given or surgery recommended but known if 
performed.  
 
Figure 2.  Summary of the Reason for No Surgery 
AA men were significantly more likely to not receive surgery as part of first course of 
treatment compared to NHW men (52.8% versus 48.38%) and significantly more likely to refuse 
surgery compared to NHW men (1.15% versus 0.74%) (Figure 3 below).  There were also 
statistically significant differences in the reason for no surgery by age at diagnosis, stage at 
diagnosis and tumor grade (Figure 4 – Figure 6 below).  Younger men, less than  65 years of 
age, were more likely to have surgery as part of first course treatment while older men, 65 years 
of age and older, were more likely to not receive surgery as part of planned first course of 
treatment.  Evaluating the reason for no surgery by stage at diagnosis indicate that men with 
regional disease were more likely to receive surgery as part of first course of treatment while 
men with localized and distant disease were more likely to not receive surgery as part of 
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planned first course of treatment.  On the other hand, men with tumor grades 1 and 4 were 
more likely to receive surgery as part of first course of treatment and men with tumor grades 2 
and 3 were more likely to not receive surgery as part of planned first course of treatment.  
Further research is needed to better understand the decision making process on the physician 
and patient side in terms of why surgery was not included as planned first course of treatment. 
 
Figure 3.  Reason for No Surgery by Race/Ethnicity 
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 Figure 4.  Reason for No Surgery Stratified by Age at Diagnosis 
 
Figure 5.  Reason for No Surgery by Stage at Diagnosis 
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 Figure 6.  Reason for No Surgery by Tumor Grade 
Part II.  Hypothesis 2/Aim 2 
Hypothesis 2 
The treatment modalities administered to African American men and Non-Hispanic White men 
newly diagnosed with prostate cancer in FL may differ from recommended treatment as per 
NCCN guidelines among men with the same stage at diagnosis/tumor grade, age at diagnosis 
and life expectancy. 
Aim 2 
To determine if the treatment modalities administered to African American men and Non-
Hispanic White men differ from the treatment recommendations of the NCCN among men with 
the same stage at diagnosis/tumor grade, age at diagnosis and life expectancy. 
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NCCN Initial Treatment Guidelines 
The steps for evaluating the NCCN guidelines for initial treatment start with a prostate 
cancer diagnosis followed by initial clinical assessment and staging workup and then a risk 
group (very low, low, intermediate, high, very high, metastatic) is determined based on the 
AJCC TNM T stage (Figure 7).  Utilizing the AJCC TNM T staging along with patient life 
expectancy the NCCN initial treatment recommendation is determined.  The AJCC TNM staging 
was created in order to estimate prognosis, examine trends in treatment, create a treatment 
plan and to determine outcomes (AJCC, 6th edition).   
 
Figure 7.  Process for Obtaining NCCN Initial Treatment Recommendation  
The NCCN initial treatment recommendations over time have changed.  For example, 
the NCCN initial treatment recommendations are different for the very low risk group, low risk 
group, intermediate risk group, high risk group and the very high risk group for the time periods 
2004-2007, 2008-2009, 2010, and 2011-2012.  The details of the NCCN initial treatment 
NCCN intitial treatment recommendation 
Expected life expectancy (<10 years versus ≥10 years) 
Determine risk group based on AJCC TNM T stage (very low, low, intermediate, high, 
very high) 
Staging workup 
Initial clinical assessment 
Initial prostate cancer diagnosis 
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recommendation based on each of the aforementioned risk groups are described in detail in 
Appendix B.  The difference in the NCCN initial treatment recommendation from 2004-2007 and 
2010 for the low risk group was that active surveillance only was added as the treatment 
recommendation and radiation therapy was removed as a recommended treatment therapy.  In 
addition, the difference in the NCCN initial treatment recommendation from 2011-2012 changed 
by including life expectancy, less than 20 years, with active surveillance being the initial 
treatment recommendation and the TNM T stage changed from T1-T2a to include T1c only, with 
the T1c group being defined as the very low risk group.   
The major difference in the NCCN initial treatment recommendations for the intermediate 
risk group was that hormone therapy was added in 2010 compared to 2004-2009 time period.  
For the high risk group there were no changes in the NCCN initial treatment recommendations 
over time.  There was a change in the NCCN initial treatment recommendation for the very high 
risk group where surgery was added as a treatment recommendation in 2008 and in 2010 
radiation therapy with or without hormone therapy was added as an initial treatment 
recommendation.  This analysis focused on compliance of the NCCN initial treatment 
recommendations from 2004-2009 because this time period include 6 years versus the other 
time periods including 1 year and 2 years, respectively.  There was consistency in the NCCN 
treatment recommendations during this time period; therefore, allowing the clinician enough 
time to implement a change in clinical practice. 
AJCC TNM T Stage 
In addition to the life expectancy variable, the American Joint Committee on Cancer 
(AJCC) TNM stage variable was used to evaluate the NCCN recommended first course of 
treatment.  The FCDS dataset included AJCC TNM stage sixth edition which represent patients 
diagnosed with prostate cancer between January 1, 2003 to December 31, 2009 and the AJCC 
TNM seventh edition which represent patients diagnosed with prostate cancer on or after 
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January 1, 2010 to current.  The total number of prostate cancer cases diagnosed from calendar 
year 2003 forward were 94,390 cases and the number of cases during the same time period 
with AJCC 6th or 7th edition TNM T stage documented in the FCDS dataset was 85,694 cases 
which indicate that 91% of the cases have TNM T stage coded so that the appropriate NCCN 
treatment recommendations can be evaluated (Table 19).  There were 8,696 (9%) of the cases 
in 2003 with missing AJCC TNM T stage. Therefore, the study population for research question 
2 was based on 85,694 cases.  Per the AJCC TNM guidelines the T stage indicates the “extent 
of the primary tumor or local tumor growth” (AJCC 6th Edition Staging Manual, 2002).     
Table 19.  Distribution of Prostate Cancer Cases by AJCC TNM T Stage, N=85,694 
 
 
AJCC TNM T Stage Count (%) 
Definition of AJCC 
TNM T Stage* 
0 2 (0.002%) 
There is no evidence of 
a primary prostate 
tumor 
T1a 714 (0.83%) 
Tumor findings in 5% 
or less of the tissue 
T1b 446 (0.52%) 
Tumor findings in 5% 
or less of the tissue 
T1c 36,431 (42.5%) 
Tumor identified by 
needle biopsy 
T1NOS 471 (0.55%) 
T1 tumor, not 
otherwise specified 
T2a 9,251 (10.8%) 
Tumor comprises ½ of 
1 lobe or less 
T2b 3,425 (4.00%) 
Tumor comprises more 
than ½ of 1 lobe but 
not both lobes 
T2c 19,512 (22.8%) 
Tumor comprises both 
lobes 
T2NOS 8,385 (9.8%) 
T2 tumor, not 
otherwise specified 
T3a 3,384 (3.9%) 
Tumor has unilateral or 
bilateral extracapsular 
extension 
T3b 1,744 (2.04%) 
Tumor has invaded the 
seminal vesicle(s) 
T3NOS 
 482 (0.56%) 
T3 tumor, not 
otherwise specified 
T4 1,039 (1.21%) Tumor has invaded 
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Table 19 (Continued) other adjacent 
structures other than 
the seminal vesicle(s) 
Unknown 408 (0.48%) 
TNM T stage not 
known 
Total  85,694  
*Source: AJCC 6th and 7th edition staging manuals 
Life Expectancy Variable 
In order to compare the treatment modalities administered and if the cases meet the 
treatment recommendations based on the NCCN guidelines, a life expectancy variable was 
created using age at diagnosis and the Social Security Administration Life Table of life 
expectancy for males.  Life expectancy was grouped into the following 3 categories in order to 
determine appropriate treatment recommendation comparisons, 1) life expectancy greater than 
or equal to 20 years, 2) life expectancy 10-19 years, 3) life expectancy less than 10 years.  
Using the current study population of 85,694 cases, AA men represent 16.5% of the 
study population and NHW men represent 83.5% of the study population.  The life expectancy 
distribution by race/ethnicity based on the 85,694 study population is represented below in 
Table 20. Stratifying life expectancy by race/ethnicity indicates that AA men were more likely to 
have a life expectancy of 20 years or more compared to NHW men (41% versus 23%).  On the 
other hand, NHW men were more likely to have a life expectancy 10-19 years (60% versus 
52%) and <10 years (15% versus 7%) compared to AA men. 
Table 20.  Life Expectancy and Race/Ethnicity for Cases with AJCC TNM T Stage, N=85,694. 
    Race/Ethnicity   
Demographic and 
Clinical 
Characteristics 
AA (n=14,176) NHW  (n=71,518) P-value 
Life Expectancy     <0.0001 
20+ years 5,746 (40.5%) 18,162 (23.4%)  
10-19 years 7,402 (52.2%) 42,732 (59.8%)  
<10 years 1,028 (7.3%) 10,624 (14.9%)  
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Assessment of Adherence to the NCCN Initial Treatment Recommendation 
Results by Race/Ethnicity 
 Evaluating the NCCN initial treatment recommendations from 2004-2009 by 
race/ethnicity indicate that low risk AA men with a life expectancy less than 10 years were less 
likely to receive the NCCN initial treatment recommendations compared to NHW men with the 
same life expectancy (5% versus 13%) (Table 21). On the other hand, AA men with 10 or more 
years of life expectancy were more likely to receive the NCCN initial treatment recommendation 
compared to NHW men (65% versus 61%).  There were no race/ethnic differences in NCCN 
initial treatment among men in the intermediate risk group with 10 or more years of life 
expectancy.  Seventy five percent (75%) of AA and NHW men with intermediate risk and 10 or 
more years of life expectancy received the NCCN initial treatment recommendations. However, 
only 2% and 5% of AA and NHW men, respectively, received the NCCN initial treatment 
recommendation among those with intermediate risk and less than 10 years of life expectancy. 
Table 21.  Summary of the Percentage of Cases that Met the NCCN Treatment 
Recommendations by AJCC T stage and Race/Ethnicity, 2004-2009. 
 
 
Race/Ethnicity 
 
AJCC TNM T Stage AA NHW 
NCCN Initial Treatment 
Recommendation 
Low Risk       
< 10 years life 
expectancy 5% 13% Expectant management or RT 
>= 10 years life 
expectancy 65% 61% 
Expectant management or RT or 
Surgery 
Intermediate Risk       
< 10 years life 
expectancy 2% 5% 
Expectant management or RT or 
Surgery 
>= 10 years life 
expectancy 75% 75% RT or Surgery 
High Risk       
All years of life 
expectancy  86% 88% Hormone + RT or RT or Surgery 
Very High Risk       
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Table 21 (Continued) 
All years of life 
expectancy   27% 23% 
2004-2007 - Hormone or RT + 
Hormone 
 All years of life 
expectancy  76% 70% 
2008-2009 - Hormone or RT + 
Hormone or Surgery 
 
Results by Age at Diagnosis 
The results by age at diagnosis indicate that none (0%) of the men in the low risk or 
intermediate risk groups less than 75 years of age with less than 10 years of life expectancy 
received the NCCN initial treatment recommendations (Table 22).  On the other hand, over 70% 
of men in the same age group, less than 75 years of age, received the NCCN initial treatment 
recommendation if they had 10 or more years of life expectancy.  Over 80% of the men in the 
high risk group received the NCCN initial treatment recommendation across all age groups.  
Among those in the very high risk group, there was 51% or more compliance with the NCCN 
initial treatment recommendations from 2008-2009 when the guideline was changed to add 
surgery as a possible treatment recommendation compared to 2004-2007 when the NCCN 
initial treatment compliance was less than 50% or less across all age groups.  There was not 
much difference in adherence to the NCCN initial treatment recommendation for the 75+ age 
group in the very high risk group over time, 50% compliance from 2004-2007 and 51% 
compliance from 2008-2009.   
Table 22.  Summary of the Percentage of Cases that Met the NCCN Treatment 
Recommendations by AJCC T stage and Age at Diagnosis, 2004-2009. 
 
 
Age at Diagnosis 
 
AJCC TNM T Stage <50  50-64 65-74 75+ 
NCCN Initial Treatment 
Recommendation 
Low Risk           
< 10 years life 
expectancy  0% 0% 0% 45% 
Expectant management or 
RT 
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Table 22 (Continued) 
>= 10 years life 
expectancy  87% 80% 72% 20% 
Expectant management or 
RT or Surgery 
Intermediate Risk           
< 10 years life 
expectancy  0% 0% 0% 35% 
Expectant management or 
RT or Surgery 
>= 10 years life 
expectancy  94% 84% 74% 21% RT or Surgery 
High Risk           
All years of life 
expectancy  89% 88% 88% 83% 
Hormone + RT or RT or 
Surgery 
Very High Risk           
All years of life 
expectancy  
20% 14% 23% 50% 2004-2007 - Hormone or RT 
+ Hormone 
All years of life 
expectancy  
70% 70% 78% 51% 2008-2009 - Hormone or RT 
+ Hormone or Surgery 
 
Results by Stage at Diagnosis 
The results by stage at diagnosis indicate that men in the high risk group had the highest 
compliance with the NCCN initial treatment recommendation across all stages of disease 
compared to those in the low risk group, intermediate risk group and the very high risk group, 
where compliance with the NCCN treatment recommendations were consistency 40% or higher 
(Table 23).  Older men, men in the low risk group with less than 10 years of life expectancy and 
men with intermediate risk with less than 10 years of life expectancy had some of the lowest 
percentages of compliance with the NCCN initial treatment recommendations. 
Table 23.  Summary of the Percentage of Cases that Met the NCCN Treatment 
Recommendations by AJCC T stage and Stage at Diagnosis, 2004-2009. 
 
 
Stage at Diagnosis 
 
AJCC TNM T Stage Localized  Regional  Distant  
NCCN Initial 
Treatment 
Recommendation 
Low Risk         
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Table 23 (Continued) 
< 10 years life 
expectancy 12% 3% 8% 
Expectant 
management or RT 
>= 10 years life 
expectancy 62% 33% 13% 
Expectant 
management or RT or 
Surgery 
Intermediate Risk         
< 10 years life 
expectancy 4% 1% 8% 
Expectant 
management or RT or 
Surgery 
>= 10 years life 
expectancy 69% 62% 14% RT or Surgery 
High Risk         
All years of life 
expectancy  50% 88% 42% 
Hormone + RT or RT 
or Surgery 
Very High Risk         
All years of life 
expectancy  0% 17% 55% 
2004-2007 - Hormone 
or RT + Hormone 
All years of life 
expectancy  0% 13 53% 
2008-2009 - Hormone 
or RT + Hormone or 
Surgery 
 
Results by Tumor Grade 
 
The results by tumor grade indicate that men in the high risk group had 81% or higher 
compliance with the NCCN initial treatment recommendation across all tumor grades (Table 24).  
Men in the low risk group with less than 10 years of life expectancy were less likely to receive 
the NCCN initial treatment recommendation with less than 15% compliance across all tumor 
grades.    On the other hand, men in the low risk group with 10 or more years of life expectancy 
had a compliance of 35% or more with the NCCN initial treatment recommendation.  Men in the 
high risk group diagnosed with tumor grade 1 had 100% compliance with the NCCN initial 
treatment recommendation.  This is the only time where 100% compliance with the NCCN initial 
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treatment recommendation was determined after evaluating age at diagnosis, stage at 
diagnosis and race/ethnicity. 
 
Table 24.  Summary of the Percentage of Cases that Met the NCCN Treatment 
Recommendations by AJCC T stage and Tumor Grade, 2004-2009. 
 
 
Tumor Grade 
 
AJCC TNM T Stage 1 2 3 4 
NCCN Initial Treatment 
Recommendation 
Low Risk           
< 10 years life 
expectancy 12% 11% 13% 12% 
Expectant management or 
RT 
>= 10 years life 
expectancy 69% 70% 47% 35% 
Expectant management or 
RT or Surgery 
Intermediate Risk           
< 10 years life 
expectancy 2% 3% 5% 2% 
Expectant management or 
RT or Surgery 
>= 10 years life 
expectancy 90% 85% 66% 61% RT or Surgery 
High Risk           
All years of life 
expectancy  100% 93% 86% 81% 
Hormone + RT or RT or 
Surgery 
Very High Risk           
All years of life 
expectancy  25% 16% 25% 24% 
2004-2007 - Hormone or RT 
+ Hormone 
All years of life 
expectancy  0% 76% 71% 61% 
2008-2009 - Hormone or RT 
+ Hormone or Surgery 
 
Summary of Findings for Research Question 2 
 In summary there were differences in the adherence of the NCCN initial treatment 
recommendations/guidelines by race/ethnicity, age at diagnosis, tumor grade and stage at 
diagnosis.  Although, the current FCDS dataset provide support that men in the high risk and 
very high risk groups are more likely to receive the NCCN initial treatment recommendation 
compared to men in the low risk group and intermediate risk group.    In addition, this study 
identified that men 75 years of age and older were less likely to receive the NCCN initial 
treatment recommendations compared to men less than 75 years of age.  Likewise, men with 
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less than 10 years of life expectancy were less likely to receive the NCCN initial treatment 
recommendations compared to men with 10 year or more life expectancy.  Further research is 
needed in this area to ascertain additional data on whether or not men are following the other 
NCCN initial treatment recommendations such as having a DRE every 12 months and a PSA 
test every 6 months.  Having this additional clinical information will enhance the usefulness and 
application of the results in clinical practice.   
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CHAPTER FIVE: DISCUSSION 
The importance of conducting research on the patterns of care among Florida residents 
with prostate cancer is that we were able to add to the current body of knowledge regarding 
disparities in treatment.  In addition, we were able to highlight areas that need additional 
research focus while continuing to enhance our understanding of why AA men were more likely 
to be diagnosed with advanced disease at a younger age compared to NHW men.  Moreover, 
we were able to determine compliance with the NCCN initial treatment recommendations.  
Study Strengths 
The primary strength of utilizing the FCDS data is that it represents a population based 
statewide Cancer Registry database.  Secondly, FCDS has achieved 12 consecutive years of 
gold status from NAACCR indicating the submission of high quality, timely and accurate data.  
Thirdly, in addition to data edit checks, cancer registries are beginning to incorporate clinical edit 
checks in order to identify missing/incomplete tumor characteristics, site specific factors and first 
course of treatment (based on Commission on Cancer National Quality Forum, ASCO, NCCN 
and NPCR).  This has already been implemented with the Commission on Cancer (CoC) 
approved programs; however, clinical edits are not currently required by NPCR or FCDS.  When 
the clinical edits are added as a requirement for FCDS data this will enhance the usefulness of 
the treatment data because there will be verification that the treatment received has been 
evaluated and reviewed for compliance to certain treatment standards.  This will further provide 
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an enhancement to the use of Cancer Registry data at the state level as a data source in 
potentially evaluating clinical pathway treatment adherence.  Lastly, utilizing the FCDS dataset 
allowed the evaluation of treatment modalities administered to PrCa cases in the State of 
Florida.  To confirm that it is possible to use FCDS data to evaluate the first course of treatment 
patterns, a study by Williams et al evaluating racial differences in treatment patterns among 
pathologically confirmed primary ovarian cancer patients utilized FCDS data (Williams et al, 
2010).  The authors concluded that AA women who were diagnosed with ovarian cancer or 
elsewhere and received all or part of first course of treatment in the State of Florida were less 
likely to receive surgery and chemotherapy, the standard care of treatment, compared to NHW 
women, adjusted OR = 0.79, 95% CI (0.68-0.91), p-value = 0.001. (Williams et al, 2010).  In 
addition, previous studies evaluated PrCa treatment patterns using data at the national level 
such as NAACCR, NCDB, SEER data, SEER-Medicare linked data; however, Florida is a 
NAACCR state but every hospital/facility in the State of Florida is not accredited by the 
American College of Surgeons Commission on Cancer who is responsible for the NCDB data 
(Shaver et al, 2004; Shimer, 2013; Mettlin, 1997).  Next, Florida is not a SEER state 
(www.SEER.cancer.gov , List of SEER Registries, 2014) so this study adds to the body of 
knowledge in treatment patterns among PrCa patients in Florida compared to those in the 
SEER states.  Finally, physicians have clinical freedom and use of expertise to best treat their 
patients and the NCCN treatment recommendations are used as a treatment guideline so one 
would not expect 100% compliance because every patient is not treated the same due to 
differences in clinical and demographic and molecular characteristics. 
Study Limitations 
The primary limitation of utilizing the FCDS data is that a researcher is not able to 
evaluate the receipt of specific chemotherapy, immunotherapy or hormone drugs/regimens at 
the cycle or dosage level because these levels of details are not required data elements to be 
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collected and/or reported by FCDS.  Secondly, the FCDS data does not allow one to determine 
whether or not a patient was seen by a specialist such as a Urologic Oncologist or if their 
prostatectomy was performed by an Urologic surgeon versus a General Surgeon.  In order to 
obtain this information data linkage with other statewide hospital data are required.  In the case 
of PrCa, this is especially important when evaluating access to care and if a patient was seen by 
a medical professional with expertise in urologic oncology (Jang et al, 2010).  The third 
limitation, is that FCDS started collecting PrCa cases that were diagnosed and treated in private 
physician offices in 2012 (Dr. Jill MacKinnon presentation at FCDS annual conference on 
7/25/13).  This opens the opportunity of potentially underestimating the number of prostate 
cancer cases in the State of Florida before 2012 if a patient was never diagnosed and/or treated 
at a hospital or facility that reported data to FCDS before 2012.  Incorporating a link to claims 
data and hospital electronic medical record data would allow one to capture the missed prostate 
patients seen in the physician offices before 2012 in order to evaluate ICD-9 diagnosis codes 
and CPT procedure codes to determine first course of treatment patterns (Hernandez et al, 
2013).  For example, linking the FCDS data to the Agency for Healthcare Administration (AHCA) 
data can provide additional treatment and co-morbidity information for the PrCa patients.  
Fourthly, Psychiatric, Military and the Veterans Administration (VA) facilities are not required to 
report their cancer cases to FCDS, they have the option of voluntarily submitting cancer cases 
to FCDS (FCDS, 2014); therefore, active duty or retired servicemen who were diagnosed at the 
VA and received all of their first course treatment at the VA may not be represented in the 
FCDS dataset.  Next, collection of salvage treatment information, recurrence data or 
progression information are not required by state or national standards so evaluating disparities 
in recurrence or progression and treatment requires manual chart abstraction.  Also, family 
history of prostate cancer is one of the strongest risk factors that we were not able to evaluate in 
this study because family history of cancer or a personal history of cancer was not a required 
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data element collected by FCDS.  In addition, socioeconomic status and income data elements 
are not routinely collected by cancer registries so this information was not available for inclusion 
in this study.  On the other hand, Gleason score was developed by Donald Gleason in 1996 and 
it is the consensus grading system for prostate cancer; however, the cancer registry did not 
implement Gleason score with the collaborative staging variables until 2004 (Epstein et al, 
2005); therefore, tumor grade was used in this study instead of Gleason score in order to have a 
consistent variable collected over the entire time period.  Finally, recurrence or treatment 
administered after a documented recurrence was not documented at the local or state level; 
therefore, adherence to the NCCN treatment guidelines for patients with a disease free time 
period that later developed persistent or recurrent disease was not evaluated in this study. 
Consistency and Inconsistency with the Literature 
The results stratified by race/ethnicity and stage at diagnosis were partially consistent 
with previous research conducted by Xiao and colleagues who utilized FCDS data to evaluate 
treatment modalities administered to localized PrCa cases (Xiao et al, 2009).  For example, the 
results from Xiao and colleagues and this study both had the same conclusion that AA men 
diagnosed with localized PrCa were more likely to receive no definitive treatment; however, the 
inconsistencies in both studies was that Xiao determined that AA men with localized disease 
were less likely to receive radiation (25.3% versus 26.6%) and no difference was obtained for 
race/ethnicity in the receipt of surgery (33.3% versus 32.7%) (Xiao et al, 2009).  The results, 
based on the adjusted OR, of this study determined that AA men with localized disease were 
more likely to receive radiation therapy (adjusted OR=1.04, 95% CI (1.01, 1.07) and less likely 
to receive surgery (adjusted OR=0.66, 95% CI (0.63, 0.68).  On the other hand, Polednak and 
Flannery determined that AA men with localized disease were less likely to receive no treatment 
(9.8% versus 10.2%) or surgery (6.8% versus 10.8%) and more likely to receive radiation 
(15.8% versus 13.5%) compared to White men (Polednak and Flannery, 1992).  Likewise, 
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Mettlin and colleagues determined that AA men were less likely to receive surgery (22.3% 
versus 29.1%) compared to White men (Mettlin et al, 1997) and Cooperberg determined that AA 
men were less likely to receive surgery (44.5% versus 50.7%) compared to White men 
(Cooperberg et al, 2010).  Also, Underwood and team evaluated localized and regional PrCa 
cases and determined that AA were less likely to receive surgery compared to White men, 
30.6% versus 35.4% (Underwood et al, 2004).  
Stewart and colleagues determined that physicians following the 2014 NCCN and AUA 
guidelines for renal cell carcinoma can miss up to 60% of recurrences due to the recommended 
short surveillance or follow-up period after a nephrectomy (Stewart et al, 2014).  This study 
highlights the point that NCCN provides treatment guidelines and each physician has clinical 
freedom to treat their patients weighing the benefits and risks of each treatment modality. 
 Regarding age at diagnosis and treatment, Skolarus and team determined that 
men 75 years of age and older were more likely to receive active surveillance (57%) compared 
to radiation therapy (37%) and surgery (6%) (Skolarus, 2014) while the results of this study 
determined that men 75 year of age and older were more likely to receive no first course of 
treatment (adjusted OR=1.19, 95% CI (1.11, 1.27)) and less likely to receive surgery (adjusted 
OR=0.56, 95% CI (0.44, 0.72)) or radiation (adjusted OR=0.72, 95% CI (0.67, 0.77)).  On the 
other hand, the results of Skolarus indicate that men 65-74 years of age were more likely to 
receive radiation (42%) versus surgery (33%) or active surveillance (Skolarus, 2014).  In 
addition, men less than 65 years of age were more likely to receive surgery (57%) versus 
radiation (25%) or active surveillance (18%).  With age at diagnosis there seems to be a shift in 
younger men, less than 65 years of age, to receive more invasive treatment modalities such as 
surgery (57%) while older men, 75 years of age and older, less likely to receive more invasive 
treatment such as surgery (6%) (Skolarus et al, 2014). 
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In summary, the results of this study have aspects that are consistent with the current 
literature, such as AA men being less likely to receive surgery as part of first course of 
treatment.  On the other hand, there is no consensus on the receipt of treatment for AA and 
NHW men regarding other treatment modalities such as radiation therapy, hormone therapy and 
no treatment.   
Public Health Importance 
 
 To highlight the Public Health Importance of this study, the results of this study can be 
used to inform both the healthcare professional and patients diagnosed with prostate cancer 
about the treatment modalities administered and how those treatment modalities compare to the 
NCCN initial treatment recommendations.  In addition, the results of this study can also be used 
to educate clinicians and other healthcare professionals that provide care to patients diagnosed 
with prostate cancer on the treatment disparities that exist by race/ethnicity, age at diagnosis, 
stage at diagnosis and tumor grade.  The results of this study are generalizable to men newly 
diagnosed with prostate cancer who received all or part of first course of treatment in the State 
of Florida and their data was reported to the Florida Cancer Data System. 
 
Future Research 
 
One of the major findings of this study is that AA men were less likely to receive surgery 
or surgery in combination with other treatment modalities compared to NHW men.  Skolarus et 
al, 2014 provide survivorship care guidelines for prostate cancer patients after they receive 
various treatment modalities and what clinicians and other healthcare providers can expect in 
terms of assisting patients in managing their health after prostate cancer diagnosis.  For 
example, the authors indicate that “treatment regret” is more common among AA men who have 
surgery (Skolarus et al, 2014).  More research is needed in this specific area to understand why 
AA men have surgical treatment regret compared to other race/ethnic groups.  For example, 
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from a qualitative research perspective, creating focus groups with the managing physicians 
and prostate cancer patients together and separately is important to better understand why AA 
men are more likely to elect palliative treatment options such as watchful waiting versus more 
curative treatment options such as active surveillance, surgery or radiation. 
From a business perspective with the Accountable Care Organizations (ACO), it will be 
important to know the cost of the extent of prostate cancer associated treatments (i.e. surgery, 
radiation therapy, hormone therapy, chemotherapy) received by patients in Florida.  Do the 
costs vary by facility, physician, geographic location in Florida, etc?  How does the cost of 
prostate cancer treatment in Florida compare to other states?  Are there disparities in the cost of 
treatment by race/ethnicity, age at diagnosis, stage at diagnosis, tumor grade for prostate 
cancer patients in the State of Florida? Also, the implementation of ACO is changing the 
payment structure of healthcare services from a fee for service to potentially a bulk payment for 
a series of services administered to a patient based on tumor grade, stage, etc. Will this affect 
payment cost of treatment as healthcare payers move from a fee for service type of payment 
system meaning that each and every service has a charge to a more value based approach 
where a payer pays a one-time fee based on the total estimated cost of treatment?  With the 
implementation of the Affordable Care Act, it will be important to see if there are any differences 
in men seeking more invasive care/treatment that have insurance, this plays along with SES 
and may possibly negate the current literature that there are differences because a patient does 
not have health insurance.  Now, the research question(s) can be asked in terms of what 
happens if a patient has health insurance?  Do we now focus on access to a medical oncologist, 
surgical oncologist, radiation oncologist, or specialist in oncology versus a general internal 
medicine physician? 
Defensible next steps that can be shared with patients are to focus on what is in their 
control such as primary prevention and modifiable risk factors.  For example, encourage men to 
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decrease red meat and fat consumption and increase consumption of vegetables and fruit.  In 
addition, 30 minutes of exercise per day, practicing safer sex that limit/reduce exposure to 
sexually transmitted diseases, having annual physical examinations and DREs (especially AA 
and high risk men under the age of 50), limit/reduce tobacco use and limit/reduce alcohol 
consumption all play a role in potentially reducing cancer risk. 
A valuable next step is to link to the FCDS data to the Centers of Medicare and Medicaid 
Services (CMS) and AHCA data in order to identify additional procedures/treatments 
administered to the patients and to identify the Medicare eligible patients to evaluate the 
treatment patterns of AA men who are 65 years of age and older.   Penberthy and colleagues 
indicate that medical claim data enhance the completeness of cancer registry treatment data 
because data from community providers increase the amount of data available for cancer 
patients (Penberthy, 2014).  Another valuable next step is to evaluate the PrCa treatment 
patterns among Hispanic men in Florida.  Hispanics represent 24% of Florida’s total population 
compared to 17% in the U.S. (US Census Bureau, 2015).  Hispanic men may have different 
treatment patterns and other barriers to receiving treatment compared to AA or NHW men.  
Also, it will be interesting to know if there are any disparities within the Hispanic community by 
comparing treatment patterns among Cuban, Puerto Rican, Mexican, Dominican Republic and 
South/Central American men.  Given Florida’s increasing population of Hispanics, this study 
would be a viable next step so that Hispanic men are aware of and receive the education 
needed in order to make appropriate health care and treatment decisions. 
 
Conclusion 
This study adds to the current body of knowledge as it relates to detectable differences 
in treatment strategies among AA men compared to NHW men in Florida newly diagnosed with 
pathologically confirmed PrCa and how these strategies embody the contemporary NCCN 
treatment recommendations.  The results of this study indicate that AA men in Florida were 
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more likely to receive radiation or hormone therapy as part of first course treatment and less 
likely to receive surgery as part of first course treatment compared to NHW men.  In addition, 
AA men in the low risk group with 10 or more years of life expectancy and AA men in the very 
high risk group were more likely to have compliance with the NCCN initial treatment 
recommendations compared to NHW men.  Further research is needed in the area of treatment 
disparities and prostate cancer in order to evaluate additional potential confounders that were 
not available for analysis in the FCDS dataset.   
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Appendix A.  Description of First Course of Treatment 
       
  
Source: FCDS, Data Acquition Manual, 2013 
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Appendix B.  NCCN Clinical Practice Guidelines for Prostate Cancer 
v1.1996 and v1.1977 
Recommended Initial Treatment Based on Clinical Stage 
T1a 
• >10 year LE or Gleason score >7 or PSA post-TUR >10ng/ml then observation or 
radiation or surgery 
T1b, T1c, T2a, T2b, T2b 
• High 
o <10 year LE – no treatment or radiation 
o 10-20 year LE – no treatment or radiation or surgery 
o >20 year LE – radiation or surgery 
• Moderate 
o <10 year LE – no treatment or radiation 
o >10 year LE – radiation or surgery 
• Low  
o <10 year LE - <10 year LE – no treatment or radiation 
o >10 year LE – radiation or surgery 
T3a 
• Androgen ablation or combination radiation and/or androgen ablation 
T3b, T3c, T4 N0 
• Androgen ablation or radiation or combination radiation and/or androgen ablation 
Tx N1-3 
• Androgen ablation and/or radiation or observation 
TxNxM1 
• Androgen ablation 
 
v1.1999 
T1a 
• Observation or radiation or surgery 
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Appendix B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NCCN Treatment Guidelines (v1.2011) Hypothesis 2/Aim 2  
Low to high risk of recurrence 
Primary Treatment 
 – T1c 
• <20 yrs = No tx/start AS 
• >=20 yrs = No tx/start AS or 
RT or HT 
– T1-T2a 
• <10 yrs = No tx/start AS 
• >=10 yrs = No tx/start AS or 
RT or HT 
– T2b-T2c 
• <10 yrs = No tx/start AS or RT 
w/ or w/o HT for 4-6 mths 
• T3a 
– RT and HT for 2-3 years or RT w/ 
or w/o HT for 4-6 mths OR Surg 
• T3b-T4 
– Same as T3a or HT only 
• Mets at Dx 
– Any T, N1, Mo 
• HT or RT and HT for 2-3 
years 
– Any T, any N, M1 
• HT 
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Appendix B 
NCCN Initial Treatment Time period, 2003-2009 
• Low risk group 
o T1-T2a 
 <10 years life expectancy 
• NCCN initial treatment recommendation is expectant management or 
radiation therapy 
 ≥ 10 years life expectancy 
• NCC initial treatment recommendation is expectant management or 
radiation therapy or surgery 
• Intermediate risk group 
o T2b-T2c 
 <10 years life expectancy 
• NCCN initial treatment recommendation is expectant management or 
radiation therapy or surgery 
 ≥ 10 years life expectancy 
• NCCN initial treatment recommendation is radiation therapy or 
surgery 
Appendix B 
• High risk group 
o T3a 
 NCCN initial treatment recommendation is radiation therapy, surgery or a 
combination of radiation therapy and hormone therapy 
 Note: there are no treatment recommendations by life expectancy 
• Very high risk group 
o T3b-T4 
 2003-2007 
• NCCN initial treatment recommendation is hormone therapy or a 
combination of hormone therapy and radiation therapy 
 2008-2009 
• NCCN initial treatment recommendation is hormone therapy, 
combination of radiation therapy and hormone therapy or surgery 
• Note: there are no treatment recommendations by life expectancy 
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Appendix B 
NCCN Initial Treatment Time period, 2010 
• Low risk group 
o T1-T2a 
 <10 years life expectancy 
• NCCN initial treatment recommendation is active surveillance 
 ≥10 years life expectancy 
• NCCN initial treatment recommendation is active surveillance, 
radiation therapy or surgery 
• Intermediate risk group 
o T2b-T2c 
 <10 years life expectancy 
• NCCN initial treatment recommendation is active surveillance or 
radiation therapy with or without hormone therapy or surgery 
 ≥10 years life expectancy 
• NCCN initial treatment recommendation is surgery or radiation 
therapy with or without  hormone therapy 
• High risk group  
o T3a 
 NCCN initial treatment recommendation is radiation therapy and hormone 
therpy or surgery 
• Very high risk group 
o T3b-T4 
 NCCN initial treatment recommendation is surgery, hormone therapy, or a 
combination of radiation therapy and hormone therapy 
• Note: there are no treatment recommendations by life expectancy 
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Appendix B 
NCCN Initial Treatment Time period, 2011-2012 
• Very low risk group 
o T1c 
 <20 years life expectancy 
• NCCN initial treatment recommendation is active surveillance 
• Low risk group 
o T1-T2a 
 <10 years life expectancy 
• NCCN initial treatment recommendation is active surveillance 
 ≥10 years life expectancy 
• NCCN initial treatment recommendation is active surveillance, 
radiation therapy or surgery 
• Intermediate risk group 
o T2b-T2c 
 <10 years life expectancy 
• NCCN initial treatment recommendation is active surveillance or 
radiation with or without hormone therapy 
 ≥10 years life expectancy 
• NCCN initial treatment recommendation is surgery or radiation 
therapy with or without hormone therapy 
• High risk group 
o T3a 
 NCCN initial treatment recommendation is surgery or radiation therapy with 
or without hormone therapy 
• Very high risk group 
o T3b-T4 
 NCCN initial treatment recommendation is hormone therapy, surgery or 
radiation therapy with or without hormone therapy 
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Appendix C.  Detailed Proposed Inclusion/Exclusion Criteria 
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Appendix D.  FCDS List of Available Data Elements 
NAACCR 
Item # 
 
Ite
m 
Na
me 
Year Started- 
Ended 
 
STAT CD1 2 
Limited 
CD 1 3 
 
Full CD 1 
4
 
Special 
Studies5 
2875 CS Site-Specific Factor 21 2010  X X X 
2876 CS Site-Specific Factor 22 2010  X X X 
2877 CS Site-Specific Factor 23 2010  X X X 
2878 CS Site-Specific Factor 24 2010  X X X 
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2879 CS Site-Specific Factor 25 2010  X X X 
2880 CS Site-Specific Factor 1 2004  X X X 
2890 CS Site-Specific Factor 2 2004  X X X 
2900 CS Site-Specific Factor 3 2004  X X X 
2910 CS Site-Specific Factor 4 2004  X X X 
2920 CS Site-Specific Factor 5 2004  X X X 
2930 CS Site-Specific Factor 6 2004  X X X 
2935 CS Version 1st 2004  X X X 
2936 CS Version Latest 2004  X X X 
2937 CS Version Input Current 2010  X X X 
2940 Derived AJCC T 2004  X X X 
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2950 Derived AJCC T Descriptor 2004  X X X 
2960 Derived AJCC N 2004  X X X 
2970 Derived AJCC N Descriptor 2004  X X X 
2980 Derived AJCC M 2004  X X X 
2990 Derived AJCC M Descriptor 2004  X X X 
3000 Derived AJCC Stage Group 2004  X X X 
3030 Derived AJCC—Flag 2004  X X X 
3040 Derived SS1977—Flag 1981 X X X X 
3050 Derived SS2000—Flag 1981 X X X X 
3250 RX Summ--Transplnt/Endocr 2003  X X X 
3400 Derived AJCC-7 T 2010  X X X 
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3402 Derived AJCC-7 T Descript 2010  X X X 
3410 Derived AJCC-7 N 2010  X X X 
3412 Derived AJCC-7 N Descript 2010  X X X 
3420 Derived AJCC-7 M 2010  X X X 
3422 Derived AJCC-7 M Descript 2010  X X X 
3430 Derived AJCC-7 Stage Grp 2010  X X X 
  Source: FCDS (9/28/2010) 
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Appendix E. Preliminary Demographic and Clinical Characteristics Tables 
Table 9.  Overall Demographic Characteristics of Prostate Cancer Cases (March 2013), 
N=356,787 (Source: FCDS Aggregate Stat CD) 
Demographic or Clinical Characteristic Frequency Percentage 
Date of Diagnosis (5 years)     
1982-1986 27740 7.77 
1987-1991 51142 14.33 
1992-1996 69342 19.44 
1997-2001 71893 20.15 
2002-2006 69065 19.36 
2007-2011 67605 18.95 
      
Primary Race     
White 313087 87.75 
Black 38522 10.8 
Other 1432 0.4 
Unknown 3746 1.05 
      
Spanish/Hispanic Origin     
Non-Hispanic 320769 89.9 
Hispanic 32512 9.11 
Unknown 3506 0.98 
      
Gender     
Male 356724 99.98 
Female 44 0.01 
Other/Unknown 19 0.01 
      
Address at Diagnosis (State)     
Florida 356787 100 
      
Sequence Number (Central)     
0 279340 78.29 
1 48573 13.61 
2 25154 7.05 
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3 3188 0.89 
4 434 0.12 
5 76 0.02 
6 18 0.01 
7 3 0 
8 1 0 
      
FCDS Age Group     
0-4 7 0 
5-9 3 0 
10-14 1 0 
15-19 11 0 
20-24 5 0 
25-29 4 0 
30-34 9 0 
35-39 103 0.03 
40-44 1005 0.28 
45-49 4330 1.21 
50-54 12963 3.63 
55-59 26656 7.47 
60-64 46117 12.93 
65-69 74769 20.96 
70-74 78421 21.98 
75-79 61177 17.15 
80-84 32547 9.12 
85+ 18643 5.23 
Unknown 16 0 
      
Marital Status at Diagnosis     
Married 266463 74.68 
Widowed, Divorced, Separated, Single 76988 21.58 
Unknown 13336 3.74 
      
Primary Payer at Diagnosis     
Not insured; not insured self-pay 4186 1.17 
Insurance NOS; Private insurance; 
Managed care, HMO, PPO, Private 
Insurance fee for service 
77899 21.83 
Medicaid; Medicaid administered 
through a managed care plan 3764 1.05 
Medicare; Medicare NOS; Medicare 
with supplement NOS; Medicare 
administered through managed care 
plan; Medicare with private 
supplement; Medicare with Medicaid 
eligibility 
137500 38.54 
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Tricare, Military, Veterans Affairs, 
Indian/Public health service 4895 1.37 
Unknown 128543 36.03 
 
 
 
 
Table 10.  Overall Clinical Characteristics of Prostate Cancer Cases (March 
2013), n= 356,787 
Clinical Characteristic Frequency Percentage 
Diagnostic Confirmation     
Positive histology 344187 96.47 
Positive cytology 2101 0.59 
Positive microscopic confirmation but 
method unknown 132 0.04 
Positive lab marker 1608 0.45 
Direct visual without microscopic 
confirmation 56 0.02 
Radiography without microscopic 
confirmation 958 0.27 
Clinical diagnosis only 799 0.22 
Unknown whether microscopic confirmed 6946 1.95 
      
SEER Summary Stage, 1977     
In situ 675 0.33 
Local 127907 62.34 
Regional/Direct Extension 15025 7.32 
Regional/Nodes Only 2483 1.21 
Regional/Direct extension and Nodes 1328 0.65 
Regional NOS 1207 0.59 
Distant/Systemic Disease 16828 8.2 
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Unknown 39723 19.36 
Missing 151611   
      
SEER Summary Stage, 2000     
In situ 73 0.05 
Local 122212 80.6 
Regional/Direct Extension 9563 6.31 
Regional/Nodes Only 604 0.4 
Regional/Direct extension and Nodes 550 0.36 
Regional NOS 37 0.02 
Distant/Systemic Disease 5368 3.54 
Unknown 13215 8.72 
Missing 205165   
      
Grade/Differentiation     
1, Grade 1 37734 10.58 
2, Grade 2 166025 46.53 
3, Grade 3 89040 24.96 
4, Grade 4 3230 0.91 
5, T-cell 1 0 
6, B-cell 1 0 
8, Natural killer cells 3 0 
9, Grade unknown 60753 17.03 
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Appendix F.  Social Security Administration, Life Expectancy Table Stratified by Exact                    
Age 
Period Life Table, 2009 
Exact age Life expectancy 
37 41 
38 40.07 
39 39.15 
40 38.23 
41 37.31 
42 36.4 
43 35.5 
44 34.6 
45 33.7 
46 32.82 
47 31.94 
48 31.06 
49 30.2 
50 29.35 
51 28.5 
52 27.66 
53 26.84 
54 26.02 
55 25.21 
56 24.41 
57 23.61 
58 22.82 
59 22.04 
60 21.27 
61 20.5 
62 19.74 
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63 18.99 
64 18.24 
65 17.51 
66 16.79 
67 16.08 
68 15.39 
69 14.7 
70 14.03 
71 13.37 
72 12.72 
73 12.09 
74 11.47 
75 10.87 
76 10.28 
77 9.71 
78 9.16 
79 8.62 
80 8.1 
81 7.6 
82 7.12 
83 6.66 
84 6.22 
85 5.8 
86 5.4 
87 5.02 
88 4.66 
89 4.33 
90 4.02 
                                 Source: http://www.ssa.gov/OACT/STATS/table4c6.html   
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Appendix G.  Applied Inclusion/Exclusion Criteria 
Site Group = 
prostate
N=356,787 cases
Sequence number 
= 0
n = 279,340
Sequence number 
≠ 0
Address at 
diagnosis state = 
Florida 
n= 279,340
 Address at 
diagnosis state ≠ 
Florida 
Behavior ≠ 
malignant
Behavior = 
malignant
n=278,873
Diagnostic 
confirmation ≠ 
pathologic
Diagnostic 
confirmation =  
pathologic only
n=268,098
Race ≠ White or 
African American
Race = White or 
African American
n=263,457
Page 1
APPLIED INCLUSION/EXCLUSION CRITERIA
Histology type = 
‘adeno’
n=227,799
Histology type ≠ 
‘Adeno’
Non-Hispanic African 
American 
n=29,087
(13%)
Non-Hispanic 
White
n=198,712
87%
‘Adeno’ defined according to the following ICDO-3 histology codes: 8410, 8141, 8143, 8147, 8200, 8211, 8255, 8260, 8262, 
8310, 8380, 8480, 8481, 8490, 8550, 8551, 8560, 8570, 8574 and 9070 (Fritz et al, 2000)
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Appendix H.  Proposed Timeline 
Detailed Timeline by Month, June 2013 – December 2014 
Month Jun-13 
Jul-
13 
Aug-
13 Sep-13 
Oct-
13 
Nov-
13 Dec-13 
Jan-
14 
Feb-
14 
Mar-
14 
Apr-
14 
May-
14 
Jun-
14 Jul-14 
Aug-
14 
Sept-
14      
Oct-
14 
Nov 
- 14 
Dec 
- 14 
Complete writing 
of dissertation 
Outline and 
Proposal 
X X X X X           
    
Defense and 
Presentation of 
Dissertation 
Proposal 
    X           
    
Obtain USF IRB 
and FDOH IRB 
approval 
     X X         
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Month 
Jun-
13 
Jul-
13 
Aug-
13 Sep-13 
Oct-
13 
Nov-
13 Dec-13 
Jan-
14 
Feb-
14 
Mar-
14 
Apr-
14 
May-
14 
Jun-
14 Jul-14 
Aug-
14 
 
Sept-
14 
 
Oct-
14 
 
Nov 
- 14 
 
Dec 
- 14 
Data Cleaning       X X X       
    
Data Analysis          X X X X X X  
    
Prepare 
Dissertation 
Results, 
Discussion and 
Conclusion 
 
                 X  X 
  
 
 
 X 
 
 
 
X 
  
Prepare 2 
manuscripts for 
submission 
                        
  
X 
 
X 
 
Preparation for 
Mock Defense                          
  
 
X 
 
 
X 
 
Dissertation 
Defense                          
   
 
X 
 
Make any 
recommended 
changes and/or 
updates to final 
dissertation                     
     
   
 
 
X 
 
 
 
X 
Submit final 
manuscripts for 
submission to 
journals                     
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(January/February 
2015) 
Work with COPH 
and Graduate 
School to submit 
dissertation in 
correct format 
and all of the 
necessary 
documentation 
for graduation 
(January – April 
2015)                     
     
    
Final preparation 
for graduation 
(April 2015)           
     
    
Graduation 
(May 2015) 
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Appendix I:  University of South Florida Institutional Review Board Approval 
Letter 
 
 
4/29/2014 
 
Vonetta Williams 
Environmental and Occupational Health 
12902 Magnolia Drive 
Mailstop: TCC-SRB, 21205 
Tampa, FL  33612 
 
RE: Expedited Approval for Initial Review 
IRB#: Pro00016727 
Title: Race/Ethnic Differences in Prostate Cancer Treatment Patterns among Newly Diagnosed 
Prostate Cancer Patients in Florida. 
 
Study Approval Period: 4/28/2014 to 4/28/2015 
 
Dear Ms. Williams: 
 
On 4/28/2014, the Institutional Review Board (IRB) reviewed and APPROVED the 
above application and all documents outlined below. 
 
Approved Item(s): 
Protocol 
Document(s): 
Proposal with Appendix 4-14-14 
 
It was the determination of the IRB that your study qualified for expedited review which 
includes activities that (1) present no more than minimal risk to human subjects, and (2) 
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involve only procedures listed in one or more of the categories outlined below. The IRB 
may review research through the expedited review procedure authorized by 
45CFR46.110 and 21 CFR 
56.110. The research proposed in this study is categorized under the following expedited 
review category: 
 
(5) Research involving materials (data, documents, records, or specimens) that have been 
collected, or will be collected solely for nonresearch purposes (such as medical treatment 
or diagnosis). 
 
Your study qualifies for a waiver of the requirements for the process of informed consent as 
outlined in the federal regulations at 45CFR46.116(d) which states that an IRB may approve a 
consent procedure which does not include, or which alters, some or all of the elements of 
informed consent. 
As the principal investigator of this study, it is your responsibility to conduct this study in 
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the 
approved research must be submitted to the IRB for review and approval by an amendment. 
 
We appreciate your dedication to the ethical conduct of human subject research at the 
University of South Florida and your continued commitment to human research protections.  
If you have any questions regarding this matter, please call 813-974-5638. 
 
Sincerely, 
 
E. Verena Jorgensen, M.D., Chairperson 
USF Institutional Review Board 
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Appendix J: National 
Comprehensive Cancer Network 
Permissions Request 
 
ARCHIVED GLS 
(INFO PURPOSES ONLY) 
 
 
 
 
 
March 27, 2014 
 
Vonetta L. Williams, MPH, CTR 
Manager, Information Shared Services 
USF Doctoral Candidate 
Moffitt Cancer Center 
Dear: 
Enclosed is a copy of the Archive NCCN Guidelines for Prostate Cancer (all versions 1996-2012) for 
your informational purposes and use in your dissertation only. You cannot represent your institution or 
your institution’s guidelines as NCCN guidelines, NCCN-approved guidelines, or as having any other 
connection to the NCCN. The following qualifications also apply: 
 
These guidelines are a work in progress that will be refined as often as new significant data 
becomes available. 
 
The NCCN guidelines are a statement of consensus of its authors regarding their views of 
currently accepted approaches to treatment.  Any clinician seeking to apply or consult any NCCN 
guideline is expected to use independent medical judgment in the context of individual clinical 
circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer 
Network makes no warranties of any kind whatsoever regarding their content, use, or application 
and disclaims any responsibility for their application or use in any way. 
 
These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights 
reserved. These guidelines and illustrations herein may not be reproduced in any form for any 
purpose without the express written permission of the NCCN. 
 
The NCCN has the complete library of oncology practices guidelines available on a flash drive and on the 
internet. To view the most recent version of the Guidelines, go online to www.nccn.org 
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Thank you for your interest in the work of the NCCN. 
Sincerely, 
Kimberly Brydges 
Kimberly Brydges 
Business Development Specialist 
National Comprehensive Cancer Network 
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Appendix K: Florida Department of Health, Bureau of Epidemiology Approval 
 
Williams, Vonetta L. 
 
 
From: Wohler, Brad <BWohler@med.miami.edu> 
Sent: Monday, June 16, 2014 12:42 PM 
To: Williams, Vonetta L. 
Cc: 'Tara.Hylton@flhealth.gov' 
Subject: RE: DOH IRB - Moffitt Request (V. Williams) 
 
 
Ms Williams, 
 
Tara Hylton has directed that this request is free of charge. 
“There will be no fee for this request as Ms. Williams is a student.” 
 
 
Brad Wohler 
Florida Cancer Data System 
P.O. Box 016960 (D4-11) 
Miami, FL 33101 
 
 Tel.: (305) 243-5527 
 Email: bwohler@med.miami.edu 
 Locator D4-11 
Fax: (305) 243-4871 
 
Overnight Courier: 
1550 NW 10th Ave, Fox Bldg Rm 410 
Miami, FL 33136 
 
The information contained in this transmission may contain privileged and confidential information, including 
patient information protected by federal and state privacy laws. It is intended only for the use of the person(s) 
named above. If you are not the intended recipient, you are hereby notified that any review, dissemination, 
distribution or duplication of this communication is strictly prohibited. If you are not the intended recipient, 
please contact the sender by reply email and destroy all copies of the original message. 
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Appendix L: American Cancer Society, Inc. Copyright License Agreement 
 
 
 
. 
 
American Cancer Society 
 
 
 
 
 
June 30, 2014 
 
COPYRIGHT LICENSE AGREEMENT 
 
Vonetta L. Williams, MPH, CTR 
Moffitt Cancer Center 
12902 Magnolia Drive 
Tampa, FL 33612 
Vonetta. Williams@Moffitt.org 
 
 
RE:PER.14.188 
 
 
Dear Ms. Williams: 
 
Inaccordance with the following terms and conditions, the American Cancer Society, Inc. 
("ACS") grants your request to reprint content and a figure from the ACS article entitled "What 
is Prostate Cancer?" in a dissertation titled "Race/Ethnic Differences in Prostate Cancer 
Treatment Patterns Among Newly Diagnosed Prostate Cancer Patients in Florida" as set forth on 
Exhibit A attached hereto and incorporated herein (the "Material"): 
 
I. The following credit line must be prominently placed on the page[s] in which the 
Material appears: 
 
"Reprinted by the permission of the American Cancer Society, Inc. All rights reserved." 
 
2. ACS grants Vonetta L. Williams the one-time, nonexclusive, nontransferable license to 
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reproduce the Material in a dissertation titled "Race/Ethnic Differences in Prostate Cancer 
Treatment Patterns Among Newly Diagnosed Prostate Cancer Patients in Florida."  The Material 
will not be sold. 
 
3. The rights granted herein are for the English language print including disability 
accessible versions and an online platform used by the University of South Florida to access 
dissertations and do not apply to revised editions, foreign language editions, or any other form of 
print or electronic media.  Use of the Material for future reproductions, translations, or any 
derivative/ancillary works without the express written consent of ACS is prohibited.  All rights 
not expressly granted herein are exclusively reserved to ACS. 
144  
 4. The Material must appear as set forth on Exhibit A. Deletions, alterations, or other 
modification of ACS content is strictly prohibited. In addition, any other use of this or other 
ACS material or information without the express written consent of ACS is prohibited. 
 
5. ACS does not endorse or promote any party or goods or services offered by third parties. 
Accordingly, the Material shall not be used in any way that gives an implied or express 
impression of affiliation with or endorsement by ACS. 
 
Upon receipt of the executed agreement, permission will be granted to reproduce the Material. 
Please return the originally executed agreement via (1) mail to the attention of TaSonja 
Hibbler, American Cancer Society, Inc., 250 Williams Street, Atlanta, GA 30303, (2) email 
to permissioureg uest@cancer.org or (3) fax to TaSonja Hibbler at 404-417-5808 . Should 
you have any questions regarding this matter, please contact TaSonja Hibbler at 404-329-7638. 
 
 
 
s;gMWre 
Printed Name: 
Date: 
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Exhibit A 
 
 
 
Chapter Two 
 
 
Revle\V of the Literature 
 
Study Background and Rationale 
 
 
Anatomv of the Prostate Gland 
 
 
Signaled by androgens, specifically testosterone, \Vhich is produced in the scrotum, the 
prostate gland is part of the ma!e reproductive system and starts developing before birth and 
continues to grow throughout puberty, with growth of the prostate gland slowing down at 
adulthood (ACS, PC Overview, 2013).  Anatomically  located inferior to the bladder and anterior 
to the rectun1, the purpose of the prostate gland is multi-faceted_   First, the prostate gland aids 
in creating fluid that protect and nourish the sperm (ACS, PC Overview, 20-13).  Secondly, the 
prostate gland, working with the nervous systen1, serves as a valve to release sperm or urine 
(ACS. PC Overview, 20 13). 
 
Figure 1. Anaton1y of the Prostate 
 
 
 
 
 
Picture retrieved from the American Cancer Society on August  '15, 2013 
(http://www.cancer.org/ cancer/prostatecancer/deta  lledguide/ prostate-cancer -what-is-prostate- 
cancer} 
146  
 
 
 
The type of tissue that comprises the prostate gland is primarily epithelial tissue_ 
Bostwick and colleagues indicate that approximately 95% of the PrCa tumors arise from the 
epithelial cells producing histology of adenocarcinoma (Bostwick et al, '1 989)_ Adenocarcinoma 
of the prostate gland will be the focus of this study; the rare PrCa histologic types that comprise 
5% of PrCa cases, such as mucinous, ductal, neuroendocrine and small cell carcinoma will not 
be addressed {Bostwick et al, 1989). 
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Appendix M. Final Inclusion/Exclusion Criteria 
Page 1
INCLUSION/EXCLUSION CRITERIA 
YEAR OF DX, 1982-2012
Include Primary Site = C619 (prostate)
N=395,951
Include Histology = 
Adenocarcinoma
N=367,861
Exclude Histology ≠ Adenocarcinoma
(mucinous, ductal, signet ring cell, adenosquamous, 
neuroendocrine, small cell ca)
N=27,223 with missing histology
Include Master sequence 
(central) number = 00 or 01
N=338,701
Exclude Master sequence number  
≠ 00 or 01
N=29,160
Include Diagnostic confirmation = pathology 
or histologic confirmation, lab marker (all 
except unknown)
N=337,872
Exclude Diagnostic confirmation  = 
unknown how cancer was diagnosed
N=829
 Primary site is equal to prostate cancer.  Analytic cases only (cases who were diagnosed and/or treated in Florida for all or part of first course treatment).  
Excluded non-analytic cases (cases who came to a Florida hospital and they had already received all of part of their first course treatment, patients who 
present with progressive, persistent or recurrence disease).  Excluded second opinions, consultations, men with BPH (benign prostate hyperplasia) and 
men with PIN III.  Sequence number is equal to 0 (exclude patients that have multiple primary tumors.  Histology is equal to adenocarcinoma only.  
Diagnostic confirmation is equal to pathology.
Include Age at diagnosis ≥ 18 years
N=337,855
Exclude Age at diagnosis < 18 years 
(N=1) and unknown age (N=17)
N=17
Include Primary Race (Race 1) = African American 
(Black) or White 
N= 332,464
11.60% of AA (38580/332464)
83.97% of total (332464/395951)
Exclude Primary Race (Race 1) ≠ African 
American (Black) or White 
N=5,391
Include Spanish/Hispanic Origin (Ethnicity) 
= Non-Hispanic or Non-Spanish
N=298,842
Exclude Spanish/Hispanic Origin 
(Ethnicity) ≠ Non-Hispanic or Non-
Spanish
N=33,622
Include behavior code = malignant
N=395,084
Exclude behavior code ≠ malignant 
(exclude in situ)
N=786
Sex = males
N=395,870
11.05% of AA (43749/395870)
99.98% of total (395870/395951)
Sex ≠ male (exclude female 
(48), herm (5), Trans (5), 
unknown (23)
N=81
Include those with a known type of reporting 
source for treatment documentation
N=298,810
Exclude those with type of reporting source = autopsy only 
or death certificate only (no opportunity for tx)
N=32
Accounting for all missing and unknown treatment data
N=244,449 
12.47% of AA (30476/244449)
62% of total (224449/395951)
 
148 
 
  
 
 
 
 
Appendix N 
Table 11.  Demographic and Clinical Characteristics of PrCa Cases by Race/Ethnicity, 
N=244,449 
    Race/Ethnicity   
Demographic and 
Clinical 
Characteristics AA (n=30,476) NHW  (n=213,973) P-value 
Stage at Diagnosis     <0.0001 
In situ 0 (0.00%) 11 (0.01%)   
Localized 
24,867 
(81.60%) 180,276 (84.25%)   
Regional 
3,058 
(10.03%) 22,863 (10.68%)   
Distant 2,551 (8.37%) 10,823 (5.06%)   
        
Age at diagnosis 
(years)     <0.0001 
Overall Average age, 
Median age and Age 
range 68.86, 69.00, 29-105   
Average age (years) 65.31 69.36   
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Median age (years) 65.00 70.00   
Age range (years) 29-105 32-104   
<50 1,295 (4.25%) 3,162 (1.48%)   
50-64 
12,485 
(40.97%) 53,993 (25.23%)   
65-74 
11,923 
(39.12%) 96,982 (45.32%)   
75+ 
4,773 
(15.66%) 59,836 (27.96%)   
        
Insurance Payer     <0.0001 
Not insured 1,025 (3.36%) 1,391 (0.65%)   
Insurance, NOS 2,074 (6.81%) 11,304 (5.28%)   
Private insurance 
8,650 
(28.38%) 37,531 (17.54%)   
Medicaid 1,050 (3.45%) 897 (0.42%)   
Medicare 
9,668 
(31.72%) 83,279 (38.92%)   
DOD/Tricare/VA 801 (2.63%) 3,532 (1.65%)   
Unknown 
7,208 
(23.65%) 76,039 (35.54%)   
        
Tumor Grade     <0.0001 
1 2,863 (9.39%) 27,002 (12.62%)   
2 
16,390 
(53.78%) 121,212 (56.65%)   
3 
10,933 
(35.87%) 63,677 (29.76%)   
4 290 (0.95%) 2,082 (0.97%)   
        
First Course 
Treatment Modality 
Received       
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No first course 
treatment 
7,096 
(23.28%) 61,968 (28.96%) <0.0001 
Surgery (singular or 
multimodality) 
6,826 
(22.40%) 40,469 (18.91%) <0.0001 
Surgery only 
6,171 
(20.25%) 36,576 (17.09%) <0.0001 
Radiation Therapy 
(singular or 
multimodality) 
13,475 
(44.20%) 94,568 (44.22%) 0.9505 
Radiation Therapy 
only 
8,331 
(27.34%) 62,061 (29.00%) <0.0001 
Surgery and 
Radiation 199 (0.65%) 1,035 (0.48%) <0.0001 
Hormone Therapy 
(singular or 
multimodality) 
8,271 
(27.14%) 50,654 (23.67%) <0.0001 
Hormone Therapy 
only 2,961 (9.72%) 16,960  (7.93%) <0.0001 
Radiation and 
Hormone Therapy 
4,718 
(15.48%) 30,216 (14.12%) <0.0001 
Surgery and 
Hormone Therapy 334 (1.10%) 2,221 (1.04%) 0.3519 
Surgery and 
Hormone Therapy 
and Radiation 
Therapy 98 (0.32%) 505 (0.24%) 0.0048 
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Chemotherapy 
(singular or 
multimodality) 152 (0.50%) 918 (0.43%) 0.0845 
Immunotherapy 
(singular or 
multimodality) 12 (0.04%) 112 (0.05%) 0.3469 
Other Therapy 
(singular or 
multimodality) 42 (0.14%) 297 (0.14%) 0.9654 
Endocrine Therapy 
(singular or 
multimodality) 367 (1.20%) 1,171 (0.55%) <0.0001 
Other Therapy (other 
tx only, 
chemotherapy only, 
endocrine therapy 
only or 
immunotherapy 
only) 568 (1.86%) 2,431 (1.14%) <0.0001 
        
Marital Status     <0.0001 
Never married 
4,780 
(15.68%) 13,572 (6.34%)   
Ever married 
24,220 
(79.47%) 193,960 (90.65%)   
Unknown 1,476 (4.84%) 6,441 (3.01%)   
        
Vital Status     <0.0001 
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Expired 
11,210 
(36.78%) 101,323 (47.35%)   
Not known to be 
expired 
19,266 
(63.22%) 112,650 (52.65%)   
        
Year of Diagnosis     <0.0001 
1982-1986 1682 (5.52%) 16,483 (7.70%)   
1987-1991 2254 (7.40%) 30,391 (14.20%)   
1992-1996 4269 (14.01%) 38,000 (17.76%)   
1997-2001 5561 (18.25%) 41,512 (19.40%)   
2002-2006 6616 (21.71%) 39,722 (18.56%)   
2007-2012 
10094 
(33.12%) 47,865 (22.37%)   
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Table 12.  Demographic and Clinical Characteristics of PrCa Cases by Race/Ethnicity and Stage at Diagnosis (N=244,438)  
Note: In Situ cases (n=11) were not included in this table 
 
  Race/Ethnicity                 
  
Localized 
(n=205,143)     
Regional 
(n=25,921)     
Distant 
(n=13,374)     
  AA (n=24,867) 
NHW 
(n=180,276) p-value 
AA 
(n=3,058) 
NHW 
(n=22,863) p-value 
AA 
(n=2,251) 
NHW 
(n=10,823) p-value 
Demographic and 
Clinical Characteristics                   
First Course Treatment 
Modality                   
No First Course 
Treatment 5,943 (23.90%) 
53,362 
(29.60%) <0.0001 
606 
(19.82%) 
6,264 
(27.40%) <0.0001 
547 
(21.44%) 
2,335 
(21.57%) 0.8842 
Surgery Only 5,057 (20.34%) 
30,003 
(16.64%) <0.0001 
1,101 
(36.00%) 
6,491 
(28.39%) <0.0001 13 (0.51%) 81 (0.75%) 0.194 
Surgery + Radiation + 
Hormone 29 (0.12%) 128 (0.07%) 0.0147 64 (2.09%) 
363 
(1.59%) 0.0393 5 (0.20%) 14 (0.13%) 0.4214 
Surgery + Radiation 86 (0.35%) 415 (0.23%) 0.0005 
110 
(3.60%) 
605 
(2.65%) 0.0026 3 (0.12%) 15 (0.14%) 0.7947 
Surgery + Hormone 254 (1.02%) 1,601 (0.89%) 0.0373 72 (2.35%) 
591 
(2.58%) 0.4483 8 (0.31%) 29 (0.27%) 0.6929 
Hormone Therapy Only 1,469 (5.91%) 9,299 (5.16%) <0.0001 
309 
(10.10%) 
2,359 
(10.32%) 0.7154 
1,183 
(46.37%) 
5,302 
(48.99%) 0.0175 
Radiation Therapy Only 7,747 (31.15%) 
57,526 
(31.91%) 0.0164 
419 
(13.70%) 
3,772 
(16.50%) <0.0001 
165 
(6.47%) 
760 
(7.02%) 0.3211 
Radiation + Hormone 4,068 (16.36%) 
26,738 
(14.83%) <0.0001 
314 
(10.27%) 
2,053 
(8.98%) 0.0202 
336 
(13.17%) 
1,425 
(13.17%) 0.9947 
Other Therapy 214 (0.86%) 1204 (0.67%) 0.0001 63 (2.06%) 
365 
(1.60%) 0.0004 
291 
(11.41%) 
862 
(7.96%) <0.0001 
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Age at diagnosis (years)     <0.0001     <0.0001     <0.0001 
Overall Average age and 
Age range (years) 68.89 (29-105)   68.77 (34-98)   72.37 (38-104)   
Average age (years) 65.15 69.41   63.40 67.23   69.19 73.12   
Median age (years) 65.00 70.00   63.00 67.00   69.00 73.00   
Age range (years) 29-105 32-104   36-95 34-98   39-104 38-101   
<50 1,080 (4.34%) 2,603 (1.44%)   
168 
(5.49%) 
438 
(1.92%)   47 (1.84%) 
121 
(1.12%)   
50-64 10,197 (41.01%) 
44,667 
(24.78%)   
1,510 
(49.38%) 
7,555 
(33.04%)   
778 
(30.50%) 
1,771 
(16.36%)   
65-74 9,912 (39.86%) 
82,115 
(45.55%)   
1,060 
(34.66%) 
10,877 
(47.57%)   
951 
(37.28%) 
3,981 
(36.78%)   
75+ 3,678 (14.79%) 
50,891 
(28.23%)   
320 
(10.46%) 
3,993 
(17.46%)   
775 
(30.38%) 
4,950 
(45.74%)   
                    
Marital Status     <0.0001     <0.0001     <0.0001 
Never married 3,814 (15.34%) 11,548 (6.41%)   
446 
(14.58%) 
1,355 
(5.93%)   
520 
(20.38%) 
668 
(6.17%)   
Ever married 19,802 (79.63%) 
163,073 
(90.46%)   
2,491 
(81.46%) 
20,975 
(91.74%)   
1927 
(75.54%) 
9903 
(91.50%)   
Unknown 1,251 (5.03%) 5,655 (3.14%)   
121 
(3.96%) 
533 
(2.33%)   
104 
(4.08%) 
252 
(2.33%)   
                    
Grade     <0.0001     <0.0001     0.0077 
1 2,559 (10.29%) 
24,884 
(13.80%)   
132 
(4.32%) 
1264 
(5.53%)   
172 
(6.74%) 
850 
(7.85%)   
2 14,379 (57.82%) 
107,788 
(59.79%)   
1,274 
(41.66%) 
10,125 
(44.29%)   
737 
(28.89%) 
3,292 
(30.42%)   
3 7,795 (31.35%) 
46,499 
(25.79%)   
1,606 
(52.52%) 
11,051 
(48.34%)   
1,532 
(60.05%) 
6,127 
(56.61%)   
155 
 
4 134 (0.54%) 1,105 (0.61%)   46 (1.50%) 
423 
(1.85%)   
110 
(4.31%) 
554 
(5.12%)   
                    
Insurance Payer     <0.0001     <0.0001     <0.0001 
Not insured 792 (3.18%) 1,102 (0.61%)   97 (3.17%) 
189 
(0.83%)   
136 
(5.33%) 
100 
(0.92%)   
Insurance, NOS 1,727 (6.94%) 9,663 (5.36%)   
275 
(8.99%) 
1,440 
(6.30%)   72 (2.82%) 
201 
(1.86%)   
Private insurance 7,597 (30.55%) 
32,929 
(18.27%)   
853 
(27.89%) 
3,991 
(17.46%)   
200 
(7.84%) 
610 
(5.64%)   
Medicaid 846 (3.40%) 736 (0.41%)   95 (3.11%) 92 (0.40%)   
109 
(4.27%) 69 (0.64%)   
Medicare 8,498 (34.17%) 
74,969 
(41.59%)   
677 
(22.14%) 
6,150 
(26.90%)   
493 
(19.33%) 
2,158 
(19.94%)   
DOD/Tricare/VA 719 (2.89%) 3,163 (1.75%)   60 (1.96%) 
300 
(1.31%)   22 (0.86%) 69 (0.64%)   
Unknown 4,688 (18.85%) 
57,714 
(32.01%)   
1,001 
(32.73%) 
10,701 
(46.80%)   
1,519 
(59.55%) 
7,616 
(70.37%)   
                    
Vital Status     <0.0001     <0.0001     <0.0001 
Expired 7,715 (31.03%) 
79,111 
(43.88%)   
1,310 
(42.84%) 
12,387 
(54.18%)   
2185 
(85.65%) 
9815 
(90.69%)   
Not known to be 
expired 17,152 (68.97%) 
101,165 
(56.12%)   
1,748 
(57.16%) 
10,476 
(45.82%)   
366 
(14.35%) 
1008 
(9.31%)   
                    
Year of Diagnosis     <0.0001     <0.0001     <0.0001 
1982-1986 931 (3.74%) 11652 (6.46%)   
137 
(4.48%) 
1657 
(7.25%)   
614 
(24.07%) 
3173 
(29.32%)   
1987-1991 1346 (5.41%) 
22275 
(12.36%)   
314 
(10.27%) 
4779 
(20.90%)   
594 
(23.28%) 
3332 
(30.79%)   
1992-1996 3150 (12.67%) 
30856 
(17.12%)   
711 
(23.25%) 
5601 
(24.50%)   
408 
(15.99%) 
1538 
(14.21%)   
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1997-2001 4732 (19.03%) 
36915 
(20.48%)   
539 
(17.63%) 
3621 
(15.84%)   
290 
(11.37%) 
976 
(9.02%)   
2002-2006 5776 (23.23%) 
35972 
(19.95%)   
548 
(17.92%) 
2973 
(13.00%)   
292 
(11.45%) 
777 
(7.18%)   
2007-2012 8932 (35.92%) 
42606 
(23.63%)   
809 
(26.46%) 
4232 
(18.51%)   
353 
(13.84%) 
1027 
(9.49%)   
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Table 13.  Adjusted Odds Ratios* (OR) and 95% Confidence Intervals of Prostate Cancer 
Patients by Treatment, Race/Ethnicity and Stage at Diagnosis.  
  
Adjusted 
OR (95% CI) 
Localized 
Stage p-value 
Adjusted 
OR (95% CI) 
Regional 
Stage p-value 
Adjusted 
OR (95% CI) 
Distant 
Stage p-value 
Treatment Modality             
No first course treatment             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.10 (1.06 - 
1.14) <0.0001 
0.89 (0.80-
0.98) 0.02 
1.10 (0.99-
1.22) 0.09 
Surgery (singular or 
multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
0.66 (0.63 - 
0.68) <0.0001 
0.63 (0.57 - 
0.71) <0.0001 
0.50 (0.34 - 
0.75) 0.0007 
Surgery only             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
0.65 (0.63-
0.68) <0.0001 
0.75 (0.67 - 
0.83) <0.0001 
0.34 (0.19 - 
0.63) 0.0005 
Radiation Therapy (singular 
or multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.04 (1.01 - 
1.07) 0.0128 
1.14 (1.05 - 
1.24) 0.003 
0.85 (0.77 - 
0.95) 0.004 
Radiation Therapy only             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.00 (0.97 - 
1.03) 0.75 
1.16 (1.03 - 
1.30) 0.01 
0.89 (0.75 - 
1.07) 0.22 
Surgery and Radiation             
White, Non-Hispanic 1.00   1.00   1.00   
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African American 
1.05 (0.83 - 
1.33)  0.70 
0.93 (0.75 - 
1.15) 0.50 
0.54 (0.15 - 
1.89) 0.34 
Hormone Therapy (singular 
or multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.20 (1.16 - 
1.24) <0.0001 
1.16 (1.06 - 
1.27) 0.001 
0.92 (0.84 - 
1.01) 0.08 
Hormone Therapy only             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.61 (1.52 - 
1.71) <0.0001 
1.41 (1.24 - 
1.61) <0.0001 
1.00 (0.92 - 
1.10) 0.9641 
Radiation and Hormone 
Therapy             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.06 (1.03 - 
1.11) 0.001 
1.18 (1.03 - 
1.34) 0.01 
0.86 (0.76 - 
0.98) 0.03 
Surgery and Hormone 
Therapy             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
0.86 (0.75 - 
0.98) 0.02 
0.66 (0.52 - 
0.85) 0.001 
0.74 (0.33 - 
1.64) 0.45 
Surgery and Hormone 
Therapy and Radiation 
Therapy             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.22 (0.81 - 
1.84) 0.3415 
0.90 (0.69 - 
1.19) 0.4717 
0.995 (0.35 
- 2.86) 0.9932 
Chemotherapy (singular or 
multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
0.99 (0.75 - 
1.33) 0.97 
0.46 (0.23 - 
0.91) 0.03 
0.80 (0.63 - 
1.01) 0.06 
Immunotherapy (singular or 
multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.07 (0.53 - 
2.15) 0.86 NA (n=12) NA (n=12) 
0.46 (0.14 - 
1.55) 0.2118 
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Other Therapy (singular or 
multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
0.68 (0.43 - 
1.08) 0.098 
1.38 (0.53 - 
3.62) 0.5127 
1.68 (0.96 - 
2.96) 0.0706 
Endocrine Therapy (singular 
or multimodality)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
2.32 (1.91 - 
2.83) <0.0001 
2.24 (1.61 - 
3.12) <0.0001 
1.54 (1.27 - 
1.86) <0.0001 
Other Therapy (other tx 
only, chemotherapy only, 
endocrine therapy only or 
immunotherapy only)             
White, Non-Hispanic 1.00   1.00   1.00   
African American 
1.49 (1.28 - 
1.73) <0.0001 
1.40 (1.06 - 
1.85) 0.02 
1.21 (1.04 - 
1.40) 0.0125 
*Adjusted for year of diagnosis, marital status, age at diagnosis, tumor grade, health insurance status and vital status 
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Table 14. Summary of Significant Treatment Patterns by Stage at Diagnosis - based on 
adjusted OR (95% CI) 
Localized Disease 
AA men more likely 
(statistically significant) 
AA men less likely 
(statistically significant) 
No first course treatment *+Surgery only or surgery in combo 
Radiation Therapy Surgery and Hormone Therapy 
Hormone therapy only or in 
combo   
Radiation and Hormone 
Therapy   
*Endocrine Therapy   
*Other Therapy   
Regional Disease 
AA men more likely 
(statistically significant) 
AA men less likely 
(statistically significant) 
Radiation Therapy only or 
Radiation in combo No first course treatment 
Hormone Therapy only or 
Hormone Therapy in combo 
*+Surgery only or surgery in 
combo 
Radiation and Hormone 
Therapy 
Surgery and Hormone 
Therapy 
*Endocrine Therapy  Chemo 
*Other Therapy    
Distant Disease 
AA men more likely 
(statistically significant) 
AA men less likely 
(statistically significant) 
*Endocrine Therapy *+Surgery only or surgery in combo 
*Other Therapy Radiation Therapy 
  Radiation and Hormone Therapy 
*=common treatment pattern(s) between all stages at diagnosis 
+=common treatment pattern(s) between stage at diagnosis, age at diagnosis and tumor grade 
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Table 15. Summary of Significant Treatment Patterns by Tumor Grade –based on adjusted OR 
and 95% CI 
Grade 1 
AA men more likely 
(statistically 
significant) 
AA men less likely 
(statistically 
significant) 
*Radiation only and 
radiation in combination 
with other treatment 
modalities 
No first course 
treatment 
*Hormone only and 
hormone in combination 
with other treatment 
modalities 
*+Surgery only or 
surgery in combination 
with other treatment 
modalities 
Other treatment   
Grade 2 
AA men more likely 
(statistically 
significant) 
AA men less likely 
(statistically 
significant) 
*Radiation only or 
radiation in combination 
with other treatment 
modalities 
*+Surgery only or 
surgery in combination 
with other treatment 
modalities 
*Hormone only or 
hormone in combination 
with other treatment 
modalities 
  
Radiation and hormone 
therapy   
Endocrine treatment only 
or in combination with 
other treatment 
modalities 
  
Other treatment   
Grade 3 
AA men more likely 
(statistically 
significant) 
AA men less likely 
(statistically 
significant) 
No first course treatment 
*+Surgery only or 
surgery in combination 
with other treatment 
modalities 
*Hormone only or 
hormone in combination 
with other treatment 
Radiation only 
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modalities 
*Radiation and hormone Radiation and surgery 
Endocrine therapy only 
or in combination with 
other treatment 
modalities 
Surgery and hormone 
therapy 
Other treatment Surgery and hormone and radiation 
  
Chemotherapy only or 
chemotherapy in 
combination with other 
treatment modalities 
Grade 4 
AA men more likely 
(statistically 
significant) 
AA men less likely 
(statistically 
significant) 
No significance No significance 
*=common treatment pattern(s) between all tumor grades 
+=common treatment pattern(s) between stage at diagnosis, age at diagnosis and tumor grade  
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Table 16.  Adjusted Odds Ratios* (OR) and 95% Confidence Intervals of Prostate Cancer 
Patients by Treatment, Race/Ethnicity and Tumor Grade. 
Treatment Modality 
Adjusted 
OR (95% 
CI) 
Tumor 
Grade 1 p-value 
Adjusted 
OR (95% 
CI) 
Tumor 
Grade 2 p-value 
Adjusted 
OR (95% 
CI) 
Tumor 
Grade 3 p-value 
Adjusted 
OR (95% 
CI) 
Tumor 
Grade 4 p-value 
No first course 
treatment                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.87 
(0.80 - 
0.94) 0.0006 
1.02 
(0.98 - 
1.07) 0.30 
1.27 
(1.20 - 
1.35) <0.0001 
0.76 
(0.55 - 
1.05) 0.0923 
Surgery (singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.55 
(0.46 - 
0.67) <0.0001 
0.68 
(0.65 - 
0.71) <0.0001 
0.57 
(0.53 - 
0.60) <0.0001 
0.78 
(0.50 - 
1.21) 0.27 
Surgery only                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.54 
(0.44 - 
0.65) <0.0001 
0.68 
(0.64 - 
0.71) <0.0001 
0.60 
(0.57 - 
0.63) <0.0001 
0.95 
(0.59 - 
1.53) 0.8189 
Radiation Therapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.14 
(1.05 - 
1.24) 0.0017 
1.09 
(1.05 - 
1.13) <0.0001 
0.99 
(0.94 - 
1.03) 0.50 
0.89 
(0.67 - 
1.18) 0.42 
Radiation Therapy only                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.13 
(1.03 - 
1.23) 0.0065 
1.04 
(1.002 - 
1.08) 0.04 
0.94 
(0.90 - 
0.99) 0.03 
0.88 
(0.59 - 
1.31) 0.53 
Surgery and Radiation                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.60 
(0.17 - 
2.10) 0.42 
1.00 
(0.79 - 
1.26) 0.99 
0.71 
(0.57 - 
0.88) 0.002 
0.50 
(0.14 - 
1.81) 0.29 
Hormone Therapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
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African American 
1.23 
(1.09 - 
1.38) 0.0007 
1.22 
(1.17 - 
1.27) <0.0001 
1.20 
(1.15 - 
1.26) <0.0001 
1.23 
(0.94 - 
1.62) 0.14 
Hormone Therapy only                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.39 
(1.18 - 
1.63) <0.0001 
1.50 
(1.40 - 
1.61) <0.0001 
1.43 
(1.34 - 
1.54) <0.0001 
1.31 
(0.96 - 
1.79) 0.093 
Radiation and Hormone 
Therapy                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.02 
(0.86 - 
1.20) 0.85 
1.09 
(1.04 - 
1.14) 0.0006 
1.08 
(1.02 - 
1.14) 0.004 
1.01 
(0.71 - 
1.46) 0.94 
Surgery and Hormone 
Therapy                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.89 
(0.47  - 
1.68) 0.72 
0.87 
(0.75 - 
1.01) 0.07 
0.62 
(0.51 - 
0.76) <0.0001 
0.54 
(0.16 - 
1.84) 0.32 
Surgery and Hormone 
Therapy and Radiation 
Therapy                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American NA (n=7) NA (n=7) 
1.10 
(0.77 - 
1.58) 0.60 
0.67 
(0.50 - 
0.89) 0.0064 
0.84 
(0.23 - 
3.05) 0.8 
Chemotherapy (singular 
or multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
2.44 
(1.41 - 
4.20) 0.0014 
1.04 
(0.76 - 
1.42) 0.82 
0.62 
(0.49 - 
0.80) 0.0002 
1.44 
(0.71 - 
2.91) 0.31 
Immunotherapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.48 
(0.06 - 
3.61) 0.47 
0.88 
(0.31 - 
2.50) 0.81 
0.77 
(0.34 - 
1.71) 0.51 NA NA 
Other Therapy (singular 
or multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.32 
(0.50 - 
3.44) 0.58 
0.98 
(0.62 - 
1.55) 0.92 
0.97 
(0.57 - 
1.65) 0.90 NA NA 
Endocrine Therapy 
(singular or 
multimodality)                 
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White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.53 
(0.80 - 
2.92) 0.1956 
2.03 
(1.65 - 
2.49) <0.0001 
1.95 
(1.65 - 
2.30) <0.0001 
1.97 
(0.89 - 
4.36) 0.0963 
Other Therapy (other tx 
only, chemotherapy 
only, endocrine therapy 
only or immunotherapy 
only)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.85 
(1.27 - 
2.69) 0.0013 
1.50 
(1.28 - 
1.76) <0.0001 
1.26 
(1.11 - 
1.44) 0.0006 
1.64 
(0.96 - 
2.81) 0.070 
*Adjusted for year of diagnosis, marital status, age at diagnosis, stage at diagnosis, health insurance status and vital 
status 
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Appendix N 
Table 17.  Summary of Significant Treatment Patterns by Age at Diagnosis – based on adjusted 
OR and 95% CI 
Age <50 
AA men more 
likely (statistically 
significant) 
AA men less likely 
(statistically 
significant) 
Radiation only or 
radiation in 
combination with 
other treatment 
modalities 
*+Surgery only or 
surgery in 
combination with 
other treatment 
modalities 
*Hormone only or 
hormone therapy in 
combination with 
other treatment 
modalities 
  
Radiation and 
hormone therapy   
Age 50-64 
AA men more 
likely (statistically 
significant) 
AA men less likely 
(statistically 
significant) 
No first course 
treatment 
*+Surgery only or 
surgery in 
combination with 
other treatment 
modalities 
Radiation only or 
radiation in 
combination with 
other treatment 
modalities 
Surgery and 
radiation 
*Hormone therapy 
only or hormone 
therapy in 
combination with 
other treatment 
modalities 
Surgery and 
hormone and 
radiation 
Radiation and 
hormone therapy   
Endocrine therapy   
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Age 65-74 
AA men more 
likely (statistically 
significant) 
AA men less likely 
(statistically 
significant) 
*Hormone therapy 
*+Surgery only or 
surgery in 
combination with 
other treatment 
modalities 
Endocrine therapy   
Other treatment   
Age 75+ 
AA men more 
likely (statistically 
significant) 
AA men less likely 
(statistically 
significant) 
No first course 
treatment 
*+Surgery only or 
surgery in 
combination with 
other treatment 
modalities 
Radiation only or 
radiation in 
combination with 
other treatment 
modalities 
Radiation and 
hormone therapy 
*Hormone therapy 
only   
Endocrine therapy   
Other treatment   
*=common treatment pattern(s) between all ages at diagnosis 
+=common treatment pattern(s) between stage at diagnosis, age at diagnosis and tumor grade  
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Appendix N 
Table 18.  Adjusted Odds Ratios* (OR) and 95% Confidence Intervals of Prostate Cancer 
Patients by Treatment, Race/Ethnicity and Age at Diagnosis   
Treatment Modality 
Adjusted 
OR (95% 
CI) Age 
at 
diagnosis 
<50 p-value 
Adjusted 
OR (95% 
CI) Age 
at 
diagnosis 
50-64 p-value 
Adjusted 
OR (95% 
CI) Age 
at 
diagnosis 
65-74 p-value 
Adjusted 
OR (95% 
CI) Age 
at 
diagnosis 
75+ p-value 
No first course 
treatment                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.03 
(0.84 - 
1.25) 0.79 
1.09 
(1.04 - 
1.15) 0.0012 
1.05 
(0.99 - 
1.10) 0.058 
1.19 
(1.11 - 
1.27) <0.0001 
Surgery (singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.71 
(0.61 - 
0.82) <0.0001 
0.65 
(0.62 - 
0.68) <0.0001 
0.62 
(0.58 - 
0.65) <0.0001 
0.56 
(0.44 - 
0.72) <0.0001 
Surgery only                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.70 
(0.61 - 
0.81) <0.0001 
0.67 
(0.64 - 
0.70) <0.0001 
0.62 
(0.58 - 
0.66) <0.0001 
0.57 
(0.44 - 
0.74) <0.0001 
Radiation Therapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.48 
(1.27 - 
1.72) <0.0001 
1.23 
(1.18 -
1.28) <0.0001 
1.03 
(0.99 - 
1.08) 0.1 
0.72 
(0.67 - 
0.77) <0.0001 
Radiation Therapy 
only                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.46 
(1.21 - <0.0001 
1.11 
(1.06 - <0.0001 
1.00 
(0.96 - 0.88 
0.83 
(0.77 - <0.0001 
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1.75) 1.16) 1.04) 0.89) 
Surgery and 
Radiation                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.02 
(0.60 - 
1.74) 0.93 
0.81 
(0.67 - 
0.98) 0.03 
0.82 
(0.61 - 
1.11) 0.20 
0.28 
(0.04 - 
2.04) 0.21 
Hormone Therapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.24 
(1.01 - 
1.53) 0.04 
1.40 
(1.33 - 
1.47) <0.0001 
1.21 
(1.16 - 
1.26) <0.0001 
0.95 
(0.89 - 
1.01) 0.12 
Hormone Therapy 
only                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.46 
(1.21 - 
1.75) <0.0001 
1.11 
(1.06 - 
1.16) <0.0001 
0.99 
(0.96 - 
1.04) 0.88 
0.83 
(0.77 - 
0.89) <0.0001 
Radiation and 
Hormone Therapy                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.43 
(1.09 - 
1.86) 0.0095 
1.36 
(1.28 - 
1.44) <0.0001 
1.05 
(0.998 - 
1.10) 0.061 
0.73 
(0.66 - 
0.79) <0.0001 
Surgery and 
Hormone Therapy                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.11 
(0.52 - 
2.36) 0.79 
0.73 
(0.55 - 
0.98) 0.034 
0.80 
(0.53 - 
1.20) 0.27 
1.05 
(0.31 - 
3.58) 0.94 
Surgery and 
Hormone Therapy 
and Radiation 
Therapy                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.11 
(0.52 - 
2.36) 0.79 
0.73 
(0.55 - 
0.98) 0.03 
0.80 
(0.53 - 
1.20) 0.27 
1.05 
(0.31 - 
3.58) 0.94 
Chemotherapy 
(singular or 
multimodality)                 
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White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.24 
(0.55 - 
2.77) 0.60 
0.79 
('0.60 - 
1.04) 0.09 
0.86 
(0.64 - 
1.16) 0.31 
0.83 
(0.55 - 
1.27) 0.39 
Immunotherapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American NA NA 
1.12 
(0.45 - 
2.78) 0.81 
0.47 
(0.15 - 
1.51) 0.20 
0.60 
(0.15 - 
2.52) 0.49 
Other Therapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
0.85 
(0.17 - 
4.30) 0.85 
0.92 
(0.53 - 
1.62) 0.78 
0.80 
(0.45 - 
1.42) 0.44 
1.35 
(0.74 - 
2.48) 0.33 
Endocrine Therapy 
(singular or 
multimodality)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.58 
(0.46 - 
5.39) 0.47 
1.86 
(1.40 - 
2.46) <0.0001 
1.86 
(1.50 - 
2.31) <0.0001 
2.05 
(1.70 - 
2.48) <0.0001 
Other Therapy (other 
tx only, 
chemotherapy only, 
endocrine therapy 
only or 
immunotherapy only)                 
White, Non-Hispanic 1.00   1.00   1.00   1.00   
African American 
1.41 
(0.77 - 
2.61) 0.27 
1.18 
(0.99 - 
1.42) 0.07 
1.29 
(1.09 - 
1.52) 0.003 
1.67 
(1.42 - 
1.97) <0.0001 
*Adjusted for year of diagnosis, marital status, tumor grade, stage at diagnosis, health insurance status and vital 
status 
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Appendix O 
List of Abbreviations 
AA:  African American 
AAFP: American Academy of Family Physicians 
AARR: Age-adjusted relative risk 
ACoS: American College of Surgeons 
ACS: American Cancer Society 
ADT: Androgen-deprived therapy 
AHCA: Agency for Healthcare Administration 
AJCC: American Joint Committee on Cancer TNM Staging System 
AOR: Adjusted odds ratio 
ASCO: American Society of Clinical Oncology  
BCC: Basal cell carcinoma of the skin 
BH: Black Hispanic 
BPH: Benign prostate hyperplasia 
CDC: Centers for Disease Control and Prevention 
CMS: Centers of Medicare and Medicaid Services 
COPH: College of Public Health at the University of South Florida 
CS: Collaborative Staging 
CT: Computed Tomography Scan 
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CTR: Certified Tumor Registrar 
CY: Calendar year 
DAM: Data Acquisition Manual 
DOD: Department of Defense 
DRE: Digital rectal examination 
EOH: Environmental and Occupational Health 
ERSPC: European Randomized Study of Screening for Prostate Cancer  
FCDS: Florida Cancer Data System  
FDA: Federal Drug Administration 
FDOH: Florida Department of Health 
FU: Follow-up  
FY: Fiscal year 
GWAS: Genome-wide Association Study 
HPV: Human Papilloma Virus 
Hx: History 
IARC: International Agency for Research on Cancer  
ICD-O-3: International Classification of Disease for Oncology, Third Edition 
ICD-9-CM: International Classification of Diseases, Ninth Edition, Clinical Modification 
ICD-10-CM: International Classification of Disease, Tenth Edition, Clinical Modification 
IRB: Institutional Review Board 
MDS: Myelodysplastic Syndrome 
ML: Milliliter 
MRI: Magnetic Resonance Imaging 
NCCN: National Comprehensive Cancer Network  
NCDB : National Cancer Data Base 
NCI : National Cancer Institute 
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NHW: Non-Hispanic White  
NPCR: National Program or Cancer Registries 
OR: odds ratio 
PADT: Primary androgen deprived therapy 
PIN III: High grade prostatic intraepithelial neoplasia 
PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
PrCa: Prostate cancer 
PSA: Prostate Specific Antigen test 
PH: Public Health  
ROC: Receiver Operating Characteristic Curve 
RR: Relative Risk 
SAS: Statistical Analysis Software 
Se: Selenium 
SEER: Surveillance, Epidemiology and End Results  
SES: Socioeconomic status 
SNP: single nucleotide polymorphism 
SSA: Social Security Administration 
STI: Sexually Transmitted Infections  
TRUS: Transrectal ultrasound guided biopsy of the prostate 
USF: University of South Florida 
USFPS TF: United States Preventative Services Task Force  
UTI: Urinary Tract Infection 
VA: Veterans Administration 
WHO: World Health Organization  
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